Takeda Pharmaceutical Co Ltd 6-K, filed Jan 29, 2026
Takeda Pharmaceutical Co Ltd (TAK)
6-K
2026-01-29
For: 2026-01-29
View Original
Added on
April 07, 2026
About this 6-K
Takeda Pharmaceutical Co Ltd filed this 6-K on January 29, 2026.
FORM 6-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Commission File Number: 001-38757
For the month of January 2026
TAKEDA PHARMACEUTICAL COMPANY LIMITED
(Translation of registrant’s name into English)
1-1, Nihonbashi-Honcho 2-Chome
Chuo-ku, Tokyo 103-8668
Japan
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information furnished on this form:
EXHIBIT
| Exhibit Number | ||||||||
| 1. | ||||||||
| 99.1 | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | ||||||||||||||
Date: January 29, 2026 | By: | /s/ Norimasa Takeda | ||||||||||||
Norimasa Takeda Chief Accounting Officer and Corporate Controller | ||||||||||||||
Earnings Report (Kessan Tanshin) for the Nine-month Period Ended December 31, 2025 (IFRS, Consolidated)
January 29, 2026
| Takeda Pharmaceutical Company Limited | Stock exchange listings: | Tokyo, Nagoya, Sapporo, Fukuoka | ||||||||||||||||||
| TSE Code: | 4502 | URL: https://www.takeda.com | ||||||||||||||||||
| Representative: | Christophe Weber, President & CEO | |||||||||||||||||||
| Contact: | Christopher O'Reilly | Telephone: +81-3-3278-2111 | Email: takeda.ir.contact@takeda.com | |||||||||||||||||
| Global Head of IR, Global Finance | ||||||||||||||||||||
Scheduled date of dividend payment commencement: - | ||
Supplementary materials for the financial statements: Yes | ||
Presentation to explain the financial statements: Yes | ||
(Million JPY, rounded to the nearest million)
| 1. | Consolidated Financial Results for the Nine-month Period Ended December 31, 2025 (April 1 to December 31, 2025) | ||||
(1)Consolidated Operating Results (year to date)
| (Percentage figures represent changes over the same period of the previous year) | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | Operating profit | Profit before tax | Net profit for the period | |||||||||||||||||||||||||||||||||||||||||||||||
| (Million JPY) | (%) | (Million JPY) | (%) | (Million JPY) | (%) | (Million JPY) | (%) | |||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2025 | 3,411,179 | (3.3) | 422,382 | 1.2 | 312,668 | 10.7 | 216,283 | 2.4 | ||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2024 | 3,528,152 | 9.8 | 417,518 | 86.3 | 282,383 | 181.5 | 211,241 | 43.5 | ||||||||||||||||||||||||||||||||||||||||||
| Net profit attributable to owners of the Company | Total comprehensive income for the period | Basic earnings per share | Diluted earnings per share | |||||||||||||||||||||||||||||||||||||||||||||||
| (Million JPY) | (%) | (Million JPY) | (%) | (JPY) | (JPY) | |||||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2025 | 216,081 | 2.4 | 1,018,673 | 157.7 | 137.31 | 135.13 | ||||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2024 | 211,083 | 43.5 | 395,293 | (36.8) | 133.71 | 131.69 | ||||||||||||||||||||||||||||||||||||||||||||
| Core Operating Profit | Core EPS | |||||||||||||||||||||||||||||||||||||||||||||||||
| (Billion JPY) | (%) | (JPY) | ||||||||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2025 | 971.6 | (3.4) | 428 | |||||||||||||||||||||||||||||||||||||||||||||||
Nine-month Period Ended December 31, 2024 | 1,006.3 | 16.3 | 443 | |||||||||||||||||||||||||||||||||||||||||||||||
(2)Consolidated Financial Position
| Total assets (Million JPY) | Total equity (Million JPY) | Equity attributable to owners of the Company (Million JPY) | Ratio of equity attributable to owners of the Company to total assets (%) | Equity attributable to owners of the Company per share (JPY) | ||||||||||||||||||||||||||||
As of December 31, 2025 | 15,408,774 | 7,644,091 | 7,642,943 | 49.6 | 4,838.54 | |||||||||||||||||||||||||||
As of March 31, 2025 | 14,248,344 | 6,935,979 | 6,935,084 | 48.7 | 4,407.01 | |||||||||||||||||||||||||||
| 2. Dividends | ||
| Annual dividends per share (JPY) | ||||||||||||||||||||||||||||||||
| 1st quarter end | 2nd quarter end | 3rd quarter end | Year-end | Total | ||||||||||||||||||||||||||||
For the Fiscal Year Ended March 31, 2025 | — | 98.00 | — | 98.00 | 196.00 | |||||||||||||||||||||||||||
For the Fiscal Year Ending March 31, 2026 | — | 100.00 | — | |||||||||||||||||||||||||||||
For the Fiscal Year Ending March 31, 2026 (Projection) | 100.00 | 200.00 | ||||||||||||||||||||||||||||||
(Note) Modifications in the dividend projection from the latest announcement: None
| 3. | Forecasts for Consolidated Operating Results (Actual Exchange Rate basis) for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026) | ||||
(Percentage figures represent changes from the previous fiscal year) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue | Operating profit | Profit before taxes | Net profit attributable to owners of the Company | Basic earnings per share | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| (Million JPY) | (%) | (Million JPY) | (%) | (Million JPY) | (%) | (Million JPY) | (%) | (JPY) | ||||||||||||||||||||||||||||||||||||||||||||||||
For the Fiscal Year Ending March 31, 2026 | 4,530,000 | (1.1) | 410,000 | 19.7 | 245,000 | 39.9 | 154,000 | 42.7 | 97.78 | |||||||||||||||||||||||||||||||||||||||||||||||
(Note) Modifications in forecasts of consolidated operating results from the latest announcement: Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Forecasts for Core financial measures are shown below. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Percentage figures represent changes from the previous fiscal year) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Core Revenue | Core Operating Profit | Core EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (Million JPY) | (%) | (Million JPY) | (%) | (JPY) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
For the Fiscal Year Ending March 31, 2026 | 4,530,000 | (1.1) | 1,150,000 | (1.1) | 486 | |||||||||||||||||||||||||||||||||||||||||||||||||||
(Note) Modifications in forecasts of consolidated operating results from the latest announcement: Yes
The definition of Core financial measures is stated in “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.
| 4. | Management Guidance (Constant Exchange Rate basis) for the Fiscal Year Ending March 31, 2026 (April 1, 2025 to March 31, 2026) | ||||
Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2026 (FY2025) has been revised from the management guidance announced on October 30, 2025.
| Core Revenue Growth | Core Operating Profit Growth | Core EPS Growth | |||||||||||||||||||||||||||||||||
| (%) | (%) | (%) | |||||||||||||||||||||||||||||||||
For the Fiscal Year Ending March 31, 2026 | Low-single-digit % decline | Low-single-digit % decline | Low-single-digit % decline | ||||||||||||||||||||||||||||||||
The definition of Constant Exchange Rate change is stated in “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.
▪Additional Information
(1) Significant changes in the scope of consolidation during the period | : No | ||||||||||
| (2) Changes in accounting policies and changes in accounting estimates | |||||||||||
| 1) Changes in accounting policies required by IFRS | : No | ||||||||||
| 2) Changes in accounting policies other than 1) | : No | ||||||||||
| 3) Changes in accounting estimates | : No | ||||||||||
| (3) Number of shares outstanding (common stock) | |||||||||||
| 1) Number of shares outstanding (including treasury stock) at period end: | |||||||||||
| December 31, 2025 | 1,590,987,809 shares | ||||||||||
| March 31, 2025 | 1,590,949,609 shares | ||||||||||
| 2) Number of shares of treasury stock at period end: | |||||||||||
| December 31, 2025 | 11,391,398 shares | ||||||||||
| March 31, 2025 | 17,299,963 shares | ||||||||||
3) Average number of outstanding shares (for the nine-month period ended December 31): | |||||||||||
| December 31, 2025 | 1,573,647,243 shares | ||||||||||
| December 31, 2024 | 1,578,670,992 shares | ||||||||||
▪Review of the attached condensed interim consolidated financial statements by certified public accountants or an audit firm: No
▪Note to ensure appropriate use of forecasts and guidance, and other noteworthy items
| • | Takeda applies International Financial Reporting Standards (IFRS), and the disclosure information in this document is based on IFRS. | |||||||||||||
| • | All forecasts and management guidance in this document are based on information and assumptions currently available to management, and do not represent a promise or guarantee to achieve these forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuations in foreign exchange rates. Should any significant event occur which requires the forecasts or guidance to be revised, Takeda will disclose it in a timely manner. | |||||||||||||
| • | For details of the forecasts for consolidated operating results and the management guidance, please refer to "1. Financial Highlights for the Nine-month Period Ended December 31, 2025 (4) Outlook for the Fiscal Year Ending March 31, 2026" on page 12. | |||||||||||||
| • | Supplementary materials for the financial statements including the Quarterly Financial Report and Earnings Presentation of the conference call on January 29, 2026, and its audio will be promptly posted on Takeda’s website. | |||||||||||||
(Takeda Website):
https://www.takeda.com/investors/financial-results/quarterly-results/
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Attachment Index
(2) Consolidated Financial Position | |||||
| [Financial Appendix] | |||||
1
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
1. Financial Highlights for the Nine-month Period Ended December 31, 2025
(1) Business Performance
(i) Consolidated Financial Results (April 1 to December 31, 2025)
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
JPY Change | % Change | % Change | ||||||||||||||||||||||||||||||
| Revenue | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | |||||||||||||||||||||||||
| Cost of sales | (1,198.1) | (1,165.9) | 32.3 | (2.7) | % | (2.4) | % | |||||||||||||||||||||||||
| Selling, general and administrative expenses | (808.9) | (792.2) | 16.7 | (2.1) | % | (1.3) | % | |||||||||||||||||||||||||
| Research and development expenses | (514.2) | (480.6) | 33.6 | (6.5) | % | (5.1) | % | |||||||||||||||||||||||||
| Amortization and impairment losses on intangible assets associated with products | (440.2) | (478.7) | (38.5) | 8.8 | % | 9.7 | % | |||||||||||||||||||||||||
| Other operating income | 16.2 | 22.7 | 6.4 | 39.7 | % | 40.3 | % | |||||||||||||||||||||||||
| Other operating expenses | (165.4) | (94.0) | 71.4 | (43.2) | % | (42.8) | % | |||||||||||||||||||||||||
| Operating profit | 417.5 | 422.4 | 4.9 | 1.2 | % | 0.1 | % | |||||||||||||||||||||||||
| Finance income and (expenses), net | (131.9) | (107.9) | 24.0 | (18.2) | % | (14.8) | % | |||||||||||||||||||||||||
| Share of loss of investments accounted for using the equity method | (3.2) | (1.8) | 1.4 | (43.2) | % | (53.5) | % | |||||||||||||||||||||||||
| Profit before tax | 282.4 | 312.7 | 30.3 | 10.7 | % | 7.7 | % | |||||||||||||||||||||||||
| Income tax expenses | (71.1) | (96.4) | (25.2) | 35.5 | % | 26.4 | % | |||||||||||||||||||||||||
| Net profit for the period | 211.2 | 216.3 | 5.0 | 2.4 | % | 1.4 | % | |||||||||||||||||||||||||
Net profit for the period attributable to owners of the Company | 211.1 | 216.1 | 5.0 | 2.4 | % | 1.4 | % | |||||||||||||||||||||||||
In this section, the amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. For additional information on CER change, see “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.
Revenue
Revenue for the nine-month period ended December 31, 2025 was JPY 3,411.2 billion (JPY -117.0 billion and -3.3% AER, -2.8% CER). The decline compared to the same period of the previous fiscal year was primarily attributable to a decrease in revenue in Neuroscience, one of our six key business areas. The decrease in Neuroscience was largely attributable to the continued impact from generic erosion of VYVANSE (for attention deficit hyperactivity disorder (“ADHD”)) in the U.S. Revenue steadily increased in our key business areas of Gastroenterology (“GI”), Plasma-Derived Therapies (“PDT”), Oncology and Vaccines, with a slight decline in revenue for Rare Diseases. Certain products faced headwinds due to the impact of the Medicare Part D redesign and 340B program expansion in the U.S., while there was stable demand in other regions and for other products. Revenue outside of our six key business areas was JPY 161.4 billion (JPY -29.5 billion and -15.4% AER, -16.6% CER).
2
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Revenue by Geographic Region
The following shows revenue by geographic region:
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
| Revenue: | JPY Change | % Change | % Change | |||||||||||||||||||||||||||||
| Japan | 324.7 | 339.5 | 14.7 | 4.5 | % | 4.5 | % | |||||||||||||||||||||||||
| United States | 1,841.4 | 1,674.1 | (167.3) | (9.1) | % | (6.9) | % | |||||||||||||||||||||||||
| Europe and Canada | 795.6 | 832.6 | 37.0 | 4.7 | % | 1.9 | % | |||||||||||||||||||||||||
Latin America | 191.2 | 191.4 | 0.1 | 0.1 | % | 0.5 | % | |||||||||||||||||||||||||
China | 133.8 | 141.1 | 7.3 | 5.4 | % | 7.4 | % | |||||||||||||||||||||||||
Asia (excluding Japan & China) | 75.4 | 72.9 | (2.4) | (3.2) | % | (1.3) | % | |||||||||||||||||||||||||
| Russia/CIS | 61.9 | 60.5 | (1.4) | (2.3) | % | (8.8) | % | |||||||||||||||||||||||||
Other* | 104.1 | 99.1 | (5.0) | (4.8) | % | (5.3) | % | |||||||||||||||||||||||||
| Total | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | |||||||||||||||||||||||||
* Other includes the Middle East, Oceania and Africa.
Revenue by Business Area
The following shows revenue by business area:
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
| Revenue: | JPY Change | % Change | % Change | |||||||||||||||||||||||||||||
| GI | 1,039.3 | 1,078.6 | 39.3 | 3.8 | % | 4.6 | % | |||||||||||||||||||||||||
| Rare Diseases | 579.0 | 574.5 | (4.6) | (0.8) | % | (0.6) | % | |||||||||||||||||||||||||
PDT | 784.2 | 790.5 | 6.3 | 0.8 | % | 1.9 | % | |||||||||||||||||||||||||
Oncology | 428.4 | 436.6 | 8.2 | 1.9 | % | 2.0 | % | |||||||||||||||||||||||||
Vaccines | 49.9 | 55.0 | 5.1 | 10.2 | % | 8.0 | % | |||||||||||||||||||||||||
Neuroscience | 456.5 | 314.5 | (142.0) | (31.1) | % | (30.4) | % | |||||||||||||||||||||||||
| Other | 190.9 | 161.4 | (29.5) | (15.4) | % | (16.6) | % | |||||||||||||||||||||||||
| Total | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | |||||||||||||||||||||||||
Year-on-year change in revenue for this nine-month period in each of our business areas was primarily attributable to the following products:
GI
In GI, revenue was JPY 1,078.6 billion (JPY +39.3 billion and +3.8% AER, +4.6% CER).
Sales of ENTYVIO (for ulcerative colitis (“UC”) and Crohn’s disease (“CD”)) were JPY 744.5 billion (JPY +45.5 billion and +6.5% AER, +7.4% CER). Sales in the U.S. were JPY 494.8 billion (JPY +18.8 billion and +4.0% AER). The increase was due to growth of the subcutaneous formulation, partially offset by unfavorable foreign exchange rates against the U.S. dollar. Sales in Europe and Canada were JPY 188.3 billion (JPY +18.5 billion and +10.9% AER). The increase was primarily due to continued patient gains through an increased use of the subcutaneous formulation, accompanied by favorable foreign exchange rates against the Euro.
Sales of RESOLOR/MOTEGRITY (for chronic idiopathic constipation) were JPY 5.7 billion (JPY -11.3 billion and -66.2% AER, -65.8% CER). The decrease was primarily due to the impact of multiple generic entrants in the U.S. beginning in January 2025.
Rare Diseases
In Rare Diseases, revenue was JPY 574.5 billion (JPY -4.6 billion and -0.8% AER, -0.6% CER).
Sales of ADVATE (for hemophilia A) were JPY 79.3 billion (JPY -7.6 billion and -8.7% AER, -8.4% CER). The decrease was primarily due to competitive pressure in the U.S.
Sales of ADYNOVATE/ADYNOVI (for hemophilia A) were JPY 43.7 billion (JPY -6.6 billion and -13.2% AER, -12.9% CER). The decrease was primarily due to competitive pressure in the U.S.
3
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Sales of ELAPRASE (for Hunter syndrome) were JPY 74.2 billion (JPY -3.0 billion and -3.8% AER, -4.1% CER). The decrease was primarily due to a sales decrease in the Growth and Emerging Markets.
Sales of LIVTENCITY (for post-transplant cytomegalovirus (“CMV”) infection/disease) were JPY 34.9 billion (JPY +10.5 billion and +42.7% AER, +43.6% CER). The increase was primarily attributable to continued performance in the U.S. market reflecting strong market penetration, complemented by continued geographical expansion in Europe and the Growth and Emerging Markets.
Sales of TAKHZYRO (for hereditary angioedema) were JPY 170.7 billion (JPY +2.6 billion and +1.6% AER, +2.4% CER). The increase was primarily due to higher sales in the Growth and Emerging Markets and Europe, supported by patient persistency and prophylactic market growth, partially offset by unfavorable foreign exchange rates against the U.S. dollar. The demand growth was modest in the U.S., offset by heightened pricing pressure from factors such as the Medicare Part D redesign.
PDT
In PDT, revenue was JPY 790.5 billion (JPY +6.3 billion and +0.8% AER, +1.9% CER).
Aggregate sales of immunoglobulin products, mainly used for the treatment of primary immunodeficiency (“PID”), chronic inflammatory demyelinating polyneuropathy (“CIDP”), and multifocal motor neuropathy (“MMN”), were JPY 593.6 billion (JPY +17.6 billion and +3.1% AER, +4.3% CER). The increase was driven by growth in subcutaneous immunoglobulin therapies, CUVITRU and HYQVIA. Sales of GAMMAGARD LIQUID/KIOVIG, which are intravenous immunoglobulin therapies, decreased primarily due to unfavorable foreign exchange rates against the U.S. dollar and the impact of the Medicare Part D redesign in the U.S.
Sales of FEIBA (for hemophilia A and B) were JPY 25.1 billion (JPY -7.8 billion and -23.6% AER, -23.1% CER). The decrease was driven by competitive pressure from recombinant therapies globally.
Aggregate sales of HEMOFIL (for hemophilia A), IMMUNATE (for hemophilia A), and IMMUNINE (for hemophilia B) were JPY 17.7 billion (JPY -3.7 billion and -17.2% AER, -18.0% CER). The decrease was primarily due to a sales decline in the Growth and Emerging Markets and Europe.
Oncology
In Oncology, revenue was JPY 436.6 billion (JPY +8.2 billion and +1.9% AER, +2.0% CER).
Sales of ADCETRIS (for malignant lymphomas) were JPY 106.8 billion (JPY +7.2 billion and +7.2% AER, +6.2% CER). The increase was led by strong demand in the Growth and Emerging Markets and Europe, accompanied by favorable foreign exchange rates against the Euro.
Sales of FRUZAQLA (for colorectal cancer) were JPY 42.9 billion (JPY +6.8 billion and +19.0% AER, +19.9% CER). The increase was primarily due to the successful launch in Europe, Canada and Japan, as it addressed a need for new treatment options in metastatic colorectal cancer. The increase was partially offset by a sales decrease in the U.S., impacted by the Medicare Part D redesign.
Sales of LEUPLIN/ENANTONE (for endometriosis, uterine fibroids, premenopausal breast cancer, prostate cancer, and other certain indications) were JPY 90.3 billion (JPY +1.1 billion and +1.2% AER, +0.8% CER). The increase was primarily due to a sales increase in Europe, accompanied by favorable foreign exchange rates against the Euro.
Sales of NINLARO (for multiple myeloma) were JPY 61.0 billion (JPY -10.5 billion and -14.6% AER, -13.7% CER). The decrease was primarily due to intensified competition and decreased demand mainly in the U.S., partially offset by a sales increase in the Growth and Emerging Markets.
Vaccines
In Vaccines, revenue was JPY 55.0 billion (JPY +5.1 billion and +10.2% AER, +8.0% CER).
Sales of QDENGA (for prevention of dengue) were JPY 37.7 billion (JPY +7.8 billion and +25.9% AER, +22.1% CER). The increase was due to post-launch growth in the Growth and Emerging Markets, driven by higher demand.
Sales of other vaccine products in aggregate decreased primarily due to the temporary suspension of shipments of MR vaccine (for prevention of measles and rubella) in Japan.
Neuroscience
In Neuroscience, revenue was JPY 314.5 billion (JPY -142.0 billion and -31.1% AER, -30.4% CER).
Sales of VYVANSE/ELVANSE (for ADHD) were JPY 155.1 billion (JPY -132.4 billion and -46.0% AER, -45.7% CER). The decrease was due to the continued impact of generic erosion mainly in the U.S.
4
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Cost of Sales
Cost of Sales was JPY 1,165.9 billion (JPY -32.3 billion and -2.7% AER, -2.4% CER). The decrease was primarily driven by an adjustment to Cost of Sales recorded in the nine-month period ended December 31, 2024, resulting from the implementation of accounting process to recognize accumulated foreign currency impacts of inventories, as well as lower revenue. The decrease was partially offset by higher costs resulting from changes in product mix, mainly reflecting the continued impact of generic erosion, particularly for VYVANSE in the U.S.
Selling, General and Administrative (SG&A) Expenses
SG&A Expenses were JPY 792.2 billion (JPY -16.7 billion and -2.1% AER, -1.3% CER). The decrease was primarily due to cost savings under the enterprise-wide efficiency program, particularly reductions in personnel expenses, as well as the appreciation of the Japanese yen against the U.S. dollar.
Research and Development (R&D) Expenses
R&D Expenses were JPY 480.6 billion (JPY -33.6 billion and -6.5% AER, -5.1% CER). The decrease was mainly due to cost reductions from the termination of certain development programs and cost savings under the enterprise-wide efficiency program. This decrease was partially offset by incremental investments in late-stage pipelines.
Amortization and Impairment Losses on Intangible Assets Associated with Products
Amortization and Impairment Losses on Intangible Assets Associated with Products were JPY 478.7 billion (JPY +38.5 billion and +8.8% AER, +9.7% CER). Amortization Expenses decreased (JPY -14.7 billion) primarily reflecting lower amortizable intangible assets and the appreciation of the Japanese yen against the U.S. dollar. Impairment Losses increased (JPY +53.3 billion) due to the larger impairment charges recorded in the nine-month period ended December 31, 2025, compared with those recorded in the nine-month period ended December 31, 2024. The impairment charges recognized in the nine-month period ended December 31, 2025 primarily include JPY 58.2 billion of impairment charges related to the gamma delta T-cell therapy platform and associated Oncology program, and impairment charges for certain other in-process R&D assets, which were recorded in large part reflecting the decision to discontinue the related research and development activities. The impairment charges in the nine-month period ended December 31, 2024 include JPY 21.5 billion impairment charge for soticlestat (TAK-935), following the failure of the Phase 3 studies to meet their primary endpoints.
Other Operating Income
Other Operating Income was JPY 22.7 billion (JPY +6.4 billion and +39.7% AER, +40.3% CER). The increase was mainly due to higher gains from Divestment of Business in the nine-month period ended December 31, 2025. Gains of JPY 17.9 billion were recognized on the completion of the sales of non-core products and MEPACT mainly in Europe and the Middle East & North Africa regions in the nine-month period ended December 31, 2025, while a gain of JPY 6.1 billion was recognized on the completion of the transfer of the manufacturing operation of TACHOSIL in the nine-month period ended December 31, 2024.
Other Operating Expenses
Other Operating Expenses were JPY 94.0 billion (JPY -71.4 billion and -43.2% AER, -42.8% CER). The decrease was primarily attributable to a JPY 68.6 billion reduction in restructuring expenses, reflecting lower costs under the enterprise-wide efficiency program for the nine-month period ended December 31, 2025. It also reflected the absence of one-time expenses related to post-trial access for terminated clinical trials, which had been recorded in the nine-month period ended December 31, 2024 as well as lower asset impairment losses. This decrease was partially offset by higher valuation reserves for pre-launch inventories.
Operating Profit
As a result of the above factors, Operating Profit was JPY 422.4 billion (JPY +4.9 billion and +1.2% AER, +0.1% CER).
Net Finance Expenses
Net Finance Expenses were JPY 107.9 billion (JPY -24.0 billion and -18.2% AER, -14.8% CER). The decrease is primarily attributable to JPY 19.4 billion impairment loss recognized in the nine-month period ended December 31, 2024, upon classification of Teva Takeda Pharma Ltd. shares to the Assets Held for Sale.
Share of Loss of Investments Accounted for Using the Equity Method
Share of Loss of Investments Accounted for Using the Equity Method was JPY 1.8 billion (JPY -1.4 billion and -43.2% AER, -53.5% CER).
5
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Profit Before Tax
As a result of the above factors, Profit Before Tax was JPY 312.7 billion (JPY +30.3 billion and +10.7% AER, +7.7% CER).
Income Tax Expenses
Income Tax Expenses were JPY 96.4 billion (JPY +25.2 billion and +35.5% AER, +26.4% CER). The increase was primarily attributable to higher Profit Before Tax and lower tax credits, partially offset by lower tax expense recognized in connection with the reassessment of the recoverability of Deferred Tax Assets in the nine-month period ended December 31, 2025.
Net Profit for the Period
As a result of the above factors, Net Profit for the Period was JPY 216.3 billion (JPY +5.0 billion and +2.4% AER, +1.4% CER) and Net Profit for the Period attributable to owners of the Company was JPY 216.1 billion (JPY +5.0 billion and +2.4% AER, +1.4% CER).
6
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(ii) Results of Core Financial Measures (April 1 to December 31, 2025)
Definition and Explanation of Core Financial Measures and Constant Exchange Rate Change
In addition to the financial statements in accordance with IFRS, Takeda uses the concept of Core Financial Measures for measuring financial performance. These measures are not defined by International Financial Reporting Standards (IFRS). See “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for additional information.
Results of Core Operations
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
JPY Change | % Change | % Change | ||||||||||||||||||||||||||||||
Core revenue | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | |||||||||||||||||||||||||
Core operating profit | 1,006.3 | 971.6 | (34.7) | (3.4) | % | (3.4) | % | |||||||||||||||||||||||||
Core net profit for the period | 699.1 | 673.8 | (25.3) | (3.6) | % | (3.4) | % | |||||||||||||||||||||||||
Core net profit for the period attributable to owners of the Company | 698.9 | 673.6 | (25.3) | (3.6) | % | (3.4) | % | |||||||||||||||||||||||||
Core EPS (yen) | 443 | 428 | (15) | (3.3) | % | (3.1) | % | |||||||||||||||||||||||||
Core Revenue
Core Revenue was JPY 3,411.2 billion (JPY -117.0 billion and -3.3% AER, -2.8% CER). The decrease was primarily attributable to a decrease in revenue in Neuroscience, largely attributable to the continued impact from generic erosion of VYVANSE in the U.S.
Takeda’s Growth and Launch Products* totaled JPY 1,768.3 billion (JPY +97.2 billion and +5.8% AER, +6.7% CER).
* Takeda’s Growth and Launch Products
GI: ENTYVIO, EOHILIA
Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA
PDT: Immunoglobulin products including GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU,
Albumin products including HUMAN ALBUMIN and FLEXBUMIN
Oncology: ALUNBRIG, FRUZAQLA
Vaccines: QDENGA
Core Operating Profit
Core Operating Profit was JPY 971.6 billion (JPY -34.7 billion and -3.4% AER, -3.4% CER). The components of Core Operating Profit are as below:
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
JPY Change | % Change | % Change | ||||||||||||||||||||||||||||||
Core revenue | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | |||||||||||||||||||||||||
Core cost of sales | (1,198.3) | (1,166.4) | 32.0 | (2.7) | % | (2.4) | % | |||||||||||||||||||||||||
Core selling, general and administrative (SG&A) expenses | (809.2) | (792.5) | 16.7 | (2.1) | % | (1.3) | % | |||||||||||||||||||||||||
Core research and development (R&D) expenses | (514.3) | (480.7) | 33.6 | (6.5) | % | (5.1) | % | |||||||||||||||||||||||||
Core operating profit | 1,006.3 | 971.6 | (34.7) | (3.4) | % | (3.4) | % | |||||||||||||||||||||||||
During the periods presented, these items fluctuated as follows:
Core Cost of Sales
Core Cost of Sales was JPY 1,166.4 billion (JPY -32.0 billion and -2.7% AER, -2.4% CER). The decrease was primarily driven by an adjustment to Cost of Sales recorded in the nine-month period ended December 31, 2024 resulting from the implementation of accounting process to recognize accumulated foreign currency impacts of inventories, as well as lower revenue. The decrease was partially offset by higher costs resulting from changes in product mix, mainly reflecting the continued impact of generic erosion, particularly for VYVANSE in the U.S.
7
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Core Selling, General and Administrative (SG&A) Expenses
Core SG&A expenses were JPY 792.5 billion (JPY -16.7 billion and -2.1% AER, -1.3% CER). The decrease was primarily due to cost savings under the enterprise-wide efficiency program, particularly reductions in personnel expenses, as well as the appreciation of the Japanese yen against the U.S. dollar.
Core Research and Development (R&D) Expenses
Core R&D expenses were JPY 480.7 billion (JPY -33.6 billion and -6.5% AER, -5.1% CER). The decrease was mainly due to cost reductions from the termination of certain development programs and cost savings under the enterprise-wide efficiency program. This decrease was partially offset by incremental investments in late-stage pipelines.
Core Net Profit for the Period
Core Net Profit for the Period was JPY 673.8 billion (JPY -25.3 billion and -3.6% AER, -3.4% CER) and Core Net Profit attributable to owners of the Company was JPY 673.6 billion (JPY -25.3 billion and -3.6% AER, -3.4% CER) and are calculated from Core Operating Profit as below:
| Billion JPY or percentage | ||||||||||||||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | AER | CER | |||||||||||||||||||||||||||||
JPY Change | % Change | % Change | ||||||||||||||||||||||||||||||
Core operating profit | 1,006.3 | 971.6 | (34.7) | (3.4) | % | (3.4) | % | |||||||||||||||||||||||||
Core finance income and (expenses), net | (106.2) | (98.9) | 7.2 | (6.8) | % | (2.5) | % | |||||||||||||||||||||||||
Core share of profit (loss) of investments accounted for using the equity method | 1.5 | 0.2 | (1.3) | (86.1) | % | (61.1) | % | |||||||||||||||||||||||||
Core profit before tax | 901.6 | 872.9 | (28.8) | (3.2) | % | (3.6) | % | |||||||||||||||||||||||||
Core income tax expenses | (202.6) | (199.1) | 3.5 | (1.7) | % | (4.5) | % | |||||||||||||||||||||||||
Core net profit for the period | 699.1 | 673.8 | (25.3) | (3.6) | % | (3.4) | % | |||||||||||||||||||||||||
Core net profit for the period attributable to owners of the Company | 698.9 | 673.6 | (25.3) | (3.6) | % | (3.4) | % | |||||||||||||||||||||||||
During the periods presented, these items fluctuated as follows:
Core Net Finance Expenses
Core Net Finance Expenses were JPY 98.9 billion (JPY -7.2 billion and -6.8% AER, -2.5% CER).
Core Share of Profit (Loss) of Investments Accounted for Using the Equity Method
Core Share of Profit of Investments Accounted for Using the Equity Method was JPY 0.2 billion (JPY -1.3 billion and -86.1% AER, -61.1% CER ).
Core Profit Before Tax
Core Profit Before Tax was JPY 872.9 billion (JPY -28.8 billion and -3.2% AER, -3.6% CER).
Core Income Tax Expenses
Core Income Tax Expenses were JPY 199.1 billion (JPY -3.5 billion and -1.7% AER, -4.5% CER). The decrease was primarily due to a reduction in Core Profit Before Tax for the nine-month period ended December 31, 2025.
Core EPS
Core EPS was JPY 428 (JPY -15 and -3.3% AER, -3.1% CER).
8
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(2) Consolidated Financial Position
| Billion JPY | ||||||||||||||||||||
| As of | Change | |||||||||||||||||||
March 31, 2025 | December 31, 2025 | |||||||||||||||||||
| Total Assets | 14,248.3 | 15,408.8 | 1,160.4 | |||||||||||||||||
| Total Liabilities | 7,312.4 | 7,764.7 | 452.3 | |||||||||||||||||
| Total Equity | 6,936.0 | 7,644.1 | 708.1 | |||||||||||||||||
Assets
Total Assets as of December 31, 2025 were JPY 15,408.8 billion (JPY +1,160.4 billion). Goodwill and Property, Plant and Equipment increased (JPY +428.8 billion and JPY +115.8 billion, respectively) mainly due to the effect of foreign currency translation. Cash and Cash Equivalents increased (JPY +269.8 billion). Inventories increased (JPY +189.8 billion) primarily driven by the effect of foreign currency translation, as well as higher finished goods related to PDT products. Total Other Financial Assets increased (JPY +159.4 billion) mainly due to changes in fair value for cross currency interest rate swaps and forward exchange contracts in Japan. These increases were partially offset by the decrease of Intangible Assets (JPY -115.9 billion) mainly due to amortization.
Liabilities
Total Liabilities as of December 31, 2025 were JPY 7,764.7 billion (JPY +452.3 billion). Total Bonds and Loans were JPY 4,853.3 billion*, which increased (JPY +338.1 billion) mainly due to the effect of foreign currency and the issuances of unsecured JPY denominated senior bonds and unsecured U.S. dollar-denominated senior guaranteed notes, offset by redemption and repayment of bonds and loans. Total Other Financial Liabilities increased (JPY +69.0 billion) primarily due to changes in fair value for forward exchange contracts.
* The carrying amount of Bonds was JPY 4,613.3 billion and that of Loans was JPY 240.0 billion as of December 31, 2025. The breakdown of Bonds and Loans' carrying amount is as follows:
Bonds:
Name of Bond (Face Value if Denominated in Foreign Currency) | Issuance | Maturity | Carrying Amount (Billion JPY) | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 500 million) | June 2015 | June 2045 | 79.8 | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 1,500 million) | September 2016 | September 2026 | 232.6 | |||||||||||||||||
| Unsecured Euro Denominated Senior Notes (EUR 3,000 million) | November 2018 | November 2026 ~ November 2030 | 549.8 | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 1,750 million) | November 2018 | November 2028 | 273.2 | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 7,000 million) | July 2020 | March 2030 ~ July 2060 | 1,090.4 | |||||||||||||||||
| Unsecured Euro Denominated Senior Notes (EUR 3,600 million) | July 2020 | July 2027 ~ July 2040 | 658.6 | |||||||||||||||||
| Unsecured JPY Denominated Senior Bonds | October 2021 | October 2031 | 249.6 | |||||||||||||||||
| Hybrid Bonds (Subordinated Bonds) | June 2024 | June 2084 | 458.3 | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 3,000 million) | July 2024 | July 2034 ~ July 2064 | 464.9 | |||||||||||||||||
| Unsecured JPY Denominated Senior Bonds | June 2025 | June 2030 ~ June 2035 | 183.6 | |||||||||||||||||
| Unsecured US Dollar Denominated Senior Notes (USD 2,400 million) | July 2025 | July 2035 ~ July 2055 | 372.3 | |||||||||||||||||
| Total | 4,613.3 | |||||||||||||||||||
9
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Loans:
Name of Loan (Face Value if Denominated in Foreign Currency) | Execution | Maturity | Carrying Amount (Billion JPY) | |||||||||||||||||
| Bilateral Loans | March 2016 ~ April 2024 | March 2026 ~ April 2031 | 200.0 | |||||||||||||||||
| Syndicated Hybrid Loans (Subordinated Loans) | October 2024 | October 2084 | 40.0 | |||||||||||||||||
| Other | 0.0 | |||||||||||||||||||
| Total | 240.0 | |||||||||||||||||||
On April 25, 2025, Takeda repaid JPY 10.0 billion in Bilateral Loans falling due. On June 12, 2025, Takeda issued JPY 184.0 billion in unsecured JPY denominated senior bonds (“JPY Bonds”) with maturity dates ranging from June 12, 2030, to June 12, 2035. The proceeds of the JPY Bonds were used to redeem commercial paper. Following this, on June 23, 2025, Takeda redeemed USD 800 million of unsecured U.S. dollar-denominated senior notes on their maturity date. Takeda has also rolled over USD 500 million Bilateral Loan, which was originally drawn down on March 31, 2025, on a monthly basis until July 3, 2025.
On July 2, 2025, Takeda issued unsecured U.S. dollar-denominated senior guaranteed notes (the "USD Notes") in an aggregate principal amount of USD 2,400 million with maturity dates of July 7, 2035 and July 7, 2055, through its indirect wholly owned finance subsidiary Takeda U.S. Financing, Inc. The proceeds of the USD Notes were primarily used to repay USD 500 million Bilateral Loan on July 3, 2025, and redeem commercial paper drawings in July 2025.
*Amounts presented in the above explanation for Bonds and Loans are based on the principal amount.
Equity
Total Equity as of December 31, 2025 was JPY 7,644.1 billion (JPY +708.1 billion). The increase of Other Components of Equity (JPY +800.8 billion) was mainly due to a change in currency translation adjustments reflecting the depreciation of the Japanese yen. This increase was partially offset by the decrease in Retained Earnings (JPY -91.9 billion), driven by the decrease of JPY 312.5 billion related to dividend payments, offset by the increase of JPY 216.1 billion from Net Profit for the Period.
10
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(3) Consolidated Cash Flows
Billion JPY | ||||||||||||||||||||
FY2024 Q3 | FY2025 Q3 | Change | ||||||||||||||||||
| Net cash from operating activities | 835.0 | 966.9 | 131.9 | |||||||||||||||||
| Net cash used in investing activities | (347.4) | (311.1) | 36.3 | |||||||||||||||||
| Net cash used in financing activities | (449.6) | (419.3) | 30.3 | |||||||||||||||||
| Net increase in cash and cash equivalents | 38.0 | 236.5 | 198.4 | |||||||||||||||||
| Cash and cash equivalents at the beginning of the year | 457.8 | 385.1 | (72.7) | |||||||||||||||||
| Effects of exchange rate changes on cash and cash equivalents | (1.7) | 33.4 | 35.1 | |||||||||||||||||
| Cash and cash equivalents at the end of the period | 494.1 | 654.9 | 160.8 | |||||||||||||||||
Net Cash from Operating Activities
Net Cash from Operating Activities was JPY 966.9 billion (JPY +131.9 billion). The increase was mainly due to favorable impacts from Changes in Assets and Liabilities primarily driven by changes in Trade and Other Receivables, favorable impacts resulting from Net Profit for the Period adjusted for non-cash items and other adjustments, and an increase of Other, net.
Net Cash used in Investing Activities
Net Cash used in Investing Activities was JPY 311.1 billion (JPY -36.3 billion). The decrease was mainly due to a decrease in cash outflow used in Acquisition of Investments, Acquisition of Option to License and Acquisition of Property, Plant and Equipment as well as an increase in Proceeds from Sales of Business, Net of Cash and Cash Equivalents Divested. This decrease was offset by higher cash outflows from Acquisition of Intangible Assets, as well as decrease of cash inflow from Proceeds from Sales and Redemption of Investments.
Net Cash used in Financing Activities
Net Cash used in Financing Activities was JPY 419.3 billion (JPY -30.3 billion). The decrease was mainly due to higher net cash inflows from the Issuance and Repayments of Bonds and Long-term Loans. This decrease was partially offset by an increase in Acquisition of Treasury Shares during the nine-month period ended December 31, 2025, and Proceeds from the Settlement of Cross Currency Interest Rate Swaps related to Bonds and Loans recorded during the nine-month period ended December 31, 2024.
11
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(4) Outlook for the Fiscal Year Ending March 31, 2026
The full year consolidated forecast for the fiscal year ending March 31, 2026 (FY2025) has been revised from the previous forecast announced on October 30, 2025 as follows:
Consolidated Forecast for the Fiscal Year Ending March 31, 2026 (FY2025)
| Billion JPY or percentage | ||||||||||||||||||||
Previous Forecast (October 30, 2025) | Revised Forecast (January 29, 2026) | JPY Change | % Change | |||||||||||||||||
| Revenue | 4,500.0 | 4,530.0 | 30.0 | 0.7 | % | |||||||||||||||
| Operating profit | 400.0 | 410.0 | 10.0 | 2.5 | % | |||||||||||||||
| Profit before tax | 243.0 | 245.0 | 2.0 | 0.8 | % | |||||||||||||||
Net profit for the year (attributable to owners of the Company) | 153.0 | 154.0 | 1.0 | 0.7 | % | |||||||||||||||
| EPS (JPY) | 97.14 | 97.78 | 0.63 | 0.7 | % | |||||||||||||||
Core revenue* | 4,500.0 | 4,530.0 | 30.0 | 0.7 | % | |||||||||||||||
Core operating profit* | 1,130.0 | 1,150.0 | 20.0 | 1.8 | % | |||||||||||||||
Core EPS (JPY)* | 479 | 486 | 7 | 1.5 | % | |||||||||||||||
* Please refer to “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for the definition.
[Revenue]
Takeda expects FY2025 revenue to be JPY 4,530.0 billion, an increase of JPY 30.0 billion, or 0.7%, from the previous forecast, primarily attributable to favorable changes in the assumptions of foreign exchange rates. This favorability more than offset product sales headwinds, including a stronger than anticipated generic erosion of VYVANSE in the U.S., as well as lower sales of plasma-derived therapies, TAKHZYRO and others.
The Core Revenue forecast has been revised in the same way as the Revenue forecast.
[Operating Profit]
Operating Profit is expected to increase by JPY 10.0 billion, or 2.5%, from the previous forecast to JPY 410.0 billion, mainly driven by higher revenue and change in the product mix, largely offset by higher amortization of intangible assets associated with products due to the changes in the assumption of foreign exchange rates to reflect a depreciated yen. Although operating expenses are also negatively affected by these foreign exchange rate changes, the impact is expected to be largely offset by incremental cost savings, including those from the enterprise-wide efficiency program, resulting in operating expenses remaining broadly flat compared to the previous forecast.
Core Operating Profit is expected to be JPY 1,150.0 billion, an increase of JPY 20.0 billion, or 1.8%.
[Net Profit for the Year (attributable to owners of the Company)]
Net Profit for the Year (attributable to owners of the Company) is expected to be JPY 154.0 billion, an increase of JPY 1.0 billion, or 0.7%, from the previous forecast. Profit Before Tax is expected to increase by JPY 2.0 billion, or 0.8%, to JPY 245.0 billion, primarily reflecting the increase in Operating Profit and the increase in net finance expenses, which are expected to increase by JPY 7.0 billion, or 4.5%, to JPY 163.0 billion due to the impact of foreign exchange rate changes. The tax expense is expected to increase as a result of higher Profit Before Tax, assuming the effective tax rate remains unchanged at approximately 37%.
Reported EPS is expected to be JPY 97.78, an increase of JPY 0.63, or 0.7%, and Core EPS is expected to be JPY 486, an increase of JPY 7, or 1.5%.
12
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Major assumptions used in preparing the FY2025 Forecast
| Billion JPY or percentage | |||||||||||||||||
| Previous Forecast (October 30, 2025) | Revised Forecast (January 29, 2026) | ||||||||||||||||
FX rates | Full Year | H2 | Full Year | Q4 | |||||||||||||
| USD/JPY EUR/JPY RUB/JPY CNY/JPY BRL/JPY | 147 JPY 170 JPY 1.8 JPY 20.5 JPY 27.0 JPY | 148 JPY 174 JPY 1.8 JPY 20.8 JPY 27.8 JPY | 150 JPY 174 JPY 1.9 JPY 21.1 JPY 27.4 JPY | 157 JPY 184 JPY 1.9 JPY 22.4 JPY 28.6 JPY | |||||||||||||
| Cost of sales | (1,590.0) | (1,595.0) | |||||||||||||||
SG&A expenses | (1,095.0) | (1,098.0) | |||||||||||||||
| R&D expenses | (685.0) | (687.0) | |||||||||||||||
| Amortization of intangible assets associated with products | (497.0) | (507.0) | |||||||||||||||
Impairment of intangible assets associated with products*2 | (110.0) | (110.0) | |||||||||||||||
| Other operating income | 27.0 | 27.0 | |||||||||||||||
Other operating expenses*3 | (150.0) | (150.0) | |||||||||||||||
Finance income and (expenses), net | (156.0) | (163.0) | |||||||||||||||
Adjusted free cash flow*1, 4 | 600.0 to 700.0 | 650.0 to 750.0 | |||||||||||||||
Capital expenditures (cash flow base)*4 | (400.0) to (450.0) | (400.0) to (450.0) | |||||||||||||||
| Depreciation and amortization (excluding intangible assets associated with products) | (220.0) | (220.0) | |||||||||||||||
Cash tax rate on adjusted EBITDA (excluding divestitures)*1 | Mid teen% | Low-teen% | |||||||||||||||
*1 Please refer to “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for the definition.
*2 Includes in-process R&D.
*3 Includes restructuring expense of JPY 56.0 billion which was disclosed in the Previous Forecast on October 30, 2025, and has not been changed in the Revised Forecast.
*4 Includes JPY 184.7 billion upfront payment to Innovent Biologics Inc in the Revised Forecast.
Management Guidance for the Fiscal Year Ending March 31, 2026 (FY2025)
Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2026 (FY2025) has been revised from the management guidance announced on October 30, 2025.
CER % Change* | |||||||||||
Previous Management Guidance (October 30, 2025) | Revised Management Guidance (January 29, 2026) | ||||||||||
Core revenue | Broadly Flat | Low-single-digit % decline | |||||||||
Core operating profit | Low-single-digit % decline | Low-single-digit % decline | |||||||||
| Core EPS | Low-single-digit % decline | Low-single-digit % decline | |||||||||
* Please refer to “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for the definition.
Other assumptions used in preparing the FY2025 Revised Forecast and the Management Guidance
•Reflect Takeda’s latest assumptions for the impact of tariffs, such as a 15% tariff on pharmaceutical products being imported into the U.S. from the European Union (EU) and Japan, as well as certain mitigation strategies including inventory management which Takeda is taking to minimize the impact. The impact from these tariff-related assumptions is expected to be immaterial.
13
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Forward looking statements
All forecasts in this document are based on information currently available to management, and do not represent a promise or guarantee to achieve these forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuations in foreign exchange rates. See “Important Notice—Forward-Looking Statements” in the Financial Appendix, including the documents mentioned therein. Should any significant event occur which requires the forecast to be revised, the Company will disclose it in a timely manner.
14
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
2. Condensed Interim Consolidated Financial Statements [IFRS] and Major Notes
(1) Condensed Interim Consolidated Statements of Profit or Loss
| JPY (millions, except per share data) | ||||||||||||||
| Nine-month Period Ended December 31, | ||||||||||||||
| 2024 | 2025 | |||||||||||||
| Revenue | 3,528,152 | 3,411,179 | ||||||||||||
| Cost of sales | (1,198,139) | (1,165,884) | ||||||||||||
| Selling, general and administrative expenses | (808,900) | (792,219) | ||||||||||||
| Research and development expenses | (514,220) | (480,604) | ||||||||||||
| Amortization and impairment losses on intangible assets associated with products | (440,158) | (478,707) | ||||||||||||
| Other operating income | 16,227 | 22,667 | ||||||||||||
| Other operating expenses | (165,444) | (94,049) | ||||||||||||
| Operating profit | 417,518 | 422,382 | ||||||||||||
| Finance income | 27,805 | 206,025 | ||||||||||||
| Finance expenses | (159,741) | (313,923) | ||||||||||||
| Share of loss of investments accounted for using the equity method | (3,199) | (1,816) | ||||||||||||
| Profit before tax | 282,383 | 312,668 | ||||||||||||
| Income tax expenses | (71,142) | (96,385) | ||||||||||||
| Net profit for the period | 211,241 | 216,283 | ||||||||||||
| Attributable to: | ||||||||||||||
| Owners of the Company | 211,083 | 216,081 | ||||||||||||
| Non-controlling interests | 158 | 202 | ||||||||||||
| Net profit for the period | 211,241 | 216,283 | ||||||||||||
| Earnings per share (JPY) | ||||||||||||||
| Basic earnings per share | 133.71 | 137.31 | ||||||||||||
| Diluted earnings per share | 131.69 | 135.13 | ||||||||||||
15
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(2) Condensed Interim Consolidated Statements of Comprehensive Income
| JPY (millions) | ||||||||||||||||||||
| Nine-month Period Ended December 31, | ||||||||||||||||||||
| 2024 | 2025 | |||||||||||||||||||
| Net profit for the period | 211,241 | 216,283 | ||||||||||||||||||
| Other comprehensive income (loss) | ||||||||||||||||||||
| Items that will not be reclassified to profit or loss: | ||||||||||||||||||||
| Changes in fair value of financial assets measured at fair value through other comprehensive income | (13,115) | 11,978 | ||||||||||||||||||
| Remeasurement of defined benefit pension plans | (2,940) | 2,169 | ||||||||||||||||||
| (16,056) | 14,146 | |||||||||||||||||||
| Items that may be reclassified subsequently to profit or loss: | ||||||||||||||||||||
| Exchange differences on translation of foreign operations | 186,025 | 763,063 | ||||||||||||||||||
| Cash flow hedges | 5,043 | 21,993 | ||||||||||||||||||
| Hedging cost | 9,147 | 3,511 | ||||||||||||||||||
| Share of other comprehensive loss of investments accounted for using the equity method | (108) | (323) | ||||||||||||||||||
| 200,107 | 788,244 | |||||||||||||||||||
| Other comprehensive income for the period, net of tax | 184,051 | 802,390 | ||||||||||||||||||
| Total comprehensive income for the period | 395,293 | 1,018,673 | ||||||||||||||||||
| Attributable to: | ||||||||||||||||||||
| Owners of the Company | 395,116 | 1,018,421 | ||||||||||||||||||
| Non-controlling interests | 176 | 252 | ||||||||||||||||||
| Total comprehensive income for the period | 395,293 | 1,018,673 | ||||||||||||||||||
16
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(3) Condensed Interim Consolidated Statements of Financial Position
| JPY (millions) | ||||||||||||||
| As of March 31, 2025 | As of December 31, 2025 | |||||||||||||
| ASSETS | ||||||||||||||
| Non-current assets: | ||||||||||||||
| Property, plant and equipment | 1,968,209 | 2,083,981 | ||||||||||||
| Goodwill | 5,324,430 | 5,753,268 | ||||||||||||
| Intangible assets | 3,631,560 | 3,515,628 | ||||||||||||
| Investments accounted for using the equity method | 10,802 | 10,189 | ||||||||||||
| Other financial assets | 351,124 | 423,979 | ||||||||||||
| Other non-current assets | 70,282 | 77,798 | ||||||||||||
| Deferred tax assets | 370,745 | 427,490 | ||||||||||||
| Total non-current assets | 11,727,152 | 12,292,334 | ||||||||||||
| Current assets: | ||||||||||||||
| Inventories | 1,217,349 | 1,407,192 | ||||||||||||
| Trade and other receivables | 709,465 | 736,464 | ||||||||||||
| Other financial assets | 20,476 | 107,004 | ||||||||||||
| Income taxes receivable | 15,789 | 21,457 | ||||||||||||
| Other current assets | 159,603 | 175,785 | ||||||||||||
| Cash and cash equivalents | 385,113 | 654,937 | ||||||||||||
| Assets held for sale | 13,397 | 13,602 | ||||||||||||
| Total current assets | 2,521,192 | 3,116,439 | ||||||||||||
| Total assets | 14,248,344 | 15,408,774 | ||||||||||||
17
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
| JPY (millions) | ||||||||||||||
| As of March 31, 2025 | As of December 31, 2025 | |||||||||||||
| LIABILITIES AND EQUITY | ||||||||||||||
| LIABILITIES | ||||||||||||||
| Non-current liabilities: | ||||||||||||||
| Bonds and loans | 3,966,326 | 4,270,174 | ||||||||||||
| Other financial liabilities | 550,900 | 568,644 | ||||||||||||
| Net defined benefit liabilities | 135,429 | 150,595 | ||||||||||||
| Income taxes payable | 317 | 3,271 | ||||||||||||
| Provisions | 35,177 | 34,061 | ||||||||||||
| Other non-current liabilities | 82,542 | 96,473 | ||||||||||||
| Deferred tax liabilities | 35,153 | 31,282 | ||||||||||||
| Total non-current liabilities | 4,805,844 | 5,154,500 | ||||||||||||
| Current liabilities: | ||||||||||||||
| Bonds and loans | 548,939 | 583,147 | ||||||||||||
| Trade and other payables | 475,541 | 467,594 | ||||||||||||
| Other financial liabilities | 219,120 | 270,333 | ||||||||||||
| Income taxes payable | 133,497 | 148,336 | ||||||||||||
| Provisions | 533,140 | 572,131 | ||||||||||||
| Other current liabilities | 596,283 | 567,858 | ||||||||||||
| Liabilities held for sale | — | 784 | ||||||||||||
| Total current liabilities | 2,506,521 | 2,610,183 | ||||||||||||
| Total liabilities | 7,312,365 | 7,764,683 | ||||||||||||
| EQUITY | ||||||||||||||
| Share capital | 1,694,685 | 1,694,763 | ||||||||||||
| Share premium | 1,775,713 | 1,751,906 | ||||||||||||
| Treasury shares | (74,815) | (49,124) | ||||||||||||
| Retained earnings | 1,187,586 | 1,095,662 | ||||||||||||
| Other components of equity | 2,351,915 | 3,152,680 | ||||||||||||
| Other comprehensive income associated with assets held for sale | — | (2,943) | ||||||||||||
| Equity attributable to owners of the Company | 6,935,084 | 7,642,943 | ||||||||||||
| Non-controlling interests | 895 | 1,147 | ||||||||||||
| Total equity | 6,935,979 | 7,644,091 | ||||||||||||
| Total liabilities and equity | 14,248,344 | 15,408,774 | ||||||||||||
18
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(4) Condensed Interim Consolidated Statements of Changes in Equity
Nine-month period ended December 31, 2024 (From April 1 to December 31, 2024)
| JPY (millions) | ||||||||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||
| Share capital | Share premium | Treasury shares | Retained earnings | Other components of equity | ||||||||||||||||||||||||||||||||||
| Exchange differences on translation of foreign operations | Changes in fair value of financial assets measured at fair value through other comprehensive income | |||||||||||||||||||||||||||||||||||||
| As of April 1, 2024 | 1,676,596 | 1,747,414 | (51,259) | 1,391,203 | 2,573,407 | 15,729 | ||||||||||||||||||||||||||||||||
| Net profit for the period | 211,083 | |||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 185,899 | (13,115) | ||||||||||||||||||||||||||||||||||||
| Comprehensive income (loss) for the period | — | — | — | 211,083 | 185,899 | (13,115) | ||||||||||||||||||||||||||||||||
| Transactions with owners: | ||||||||||||||||||||||||||||||||||||||
| Issuance of new shares | 18,064 | 18,064 | ||||||||||||||||||||||||||||||||||||
| Acquisition of treasury shares | (1,924) | |||||||||||||||||||||||||||||||||||||
| Disposal of treasury shares | 0 | 0 | ||||||||||||||||||||||||||||||||||||
| Dividends | (303,179) | |||||||||||||||||||||||||||||||||||||
| Transfers from other components of equity | (8,158) | 5,218 | ||||||||||||||||||||||||||||||||||||
| Share-based compensation | 54,997 | |||||||||||||||||||||||||||||||||||||
| Exercise of share-based awards | (64,476) | 28,348 | ||||||||||||||||||||||||||||||||||||
| Total transactions with owners | 18,064 | 8,585 | 26,424 | (311,338) | — | 5,218 | ||||||||||||||||||||||||||||||||
| As of December 31, 2024 | 1,694,660 | 1,755,999 | (24,835) | 1,290,948 | 2,759,307 | 7,832 | ||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other components of equity | Other comprehensive income related to assets held for sale | Total equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow hedges | Hedging cost | Remeasurements of defined benefit pension plans | Total other components of equity | Non- controlling interests | Total equity | |||||||||||||||||||||||||||||||||||||||||||||
| As of April 1, 2024 | (63,896) | (15,930) | — | 2,509,310 | — | 7,273,264 | 741 | 7,274,005 | ||||||||||||||||||||||||||||||||||||||||||
| Net profit for the period | — | 211,083 | 158 | 211,241 | ||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 5,043 | 9,147 | (2,940) | 184,033 | 184,033 | 18 | 184,051 | |||||||||||||||||||||||||||||||||||||||||||
| Comprehensive income (loss) for the period | 5,043 | 9,147 | (2,940) | 184,033 | — | 395,116 | 176 | 395,293 | ||||||||||||||||||||||||||||||||||||||||||
| Transactions with owners: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of new shares | — | 36,128 | 36,128 | |||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition of treasury shares | — | (1,924) | (1,924) | |||||||||||||||||||||||||||||||||||||||||||||||
| Disposal of treasury shares | — | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends | — | (303,179) | (303,179) | |||||||||||||||||||||||||||||||||||||||||||||||
| Transfers from other components of equity | 2,940 | 8,158 | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | — | 54,997 | 54,997 | |||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of share-based awards | — | (36,129) | (36,129) | |||||||||||||||||||||||||||||||||||||||||||||||
| Total transactions with owners | — | — | 2,940 | 8,158 | — | (250,106) | — | (250,106) | ||||||||||||||||||||||||||||||||||||||||||
| As of December 31, 2024 | (58,854) | (6,783) | — | 2,701,502 | — | 7,418,274 | 917 | 7,419,191 | ||||||||||||||||||||||||||||||||||||||||||
19
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
Nine-month period ended December 31, 2025 (From April 1 to December 31, 2025)
| JPY (millions) | ||||||||||||||||||||||||||||||||||||||
| Equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||
| Share capital | Share premium | Treasury shares | Retained earnings | Other components of equity | ||||||||||||||||||||||||||||||||||
| Exchange differences on translation of foreign operations | Changes in fair value of financial assets measured at fair value through other comprehensive income | |||||||||||||||||||||||||||||||||||||
| As of April 1, 2025 | 1,694,685 | 1,775,713 | (74,815) | 1,187,586 | 2,419,978 | 4,757 | ||||||||||||||||||||||||||||||||
| Net profit for the period | 216,081 | |||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 762,690 | 11,978 | ||||||||||||||||||||||||||||||||||||
| Comprehensive income (loss) for the period | — | — | — | 216,081 | 762,690 | 11,978 | ||||||||||||||||||||||||||||||||
| Transactions with owners: | ||||||||||||||||||||||||||||||||||||||
| Issuance of new shares | 78 | 78 | ||||||||||||||||||||||||||||||||||||
| Acquisition of treasury shares | (20) | (51,614) | ||||||||||||||||||||||||||||||||||||
| Dividends | (312,524) | |||||||||||||||||||||||||||||||||||||
| Transfers from other components of equity | 4,519 | (2,350) | ||||||||||||||||||||||||||||||||||||
| Share-based compensation | 53,439 | |||||||||||||||||||||||||||||||||||||
| Exercise of share-based awards | (77,305) | 77,305 | ||||||||||||||||||||||||||||||||||||
| Transfer to other comprehensive income associated with assets held for sale | 2,943 | |||||||||||||||||||||||||||||||||||||
| Total transactions with owners | 78 | (23,808) | 25,692 | (308,005) | 2,943 | (2,350) | ||||||||||||||||||||||||||||||||
| As of December 31, 2025 | 1,694,763 | 1,751,906 | (49,124) | 1,095,662 | 3,185,611 | 14,385 | ||||||||||||||||||||||||||||||||
Equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Other components of equity | Other comprehensive income related to assets held for sale | Total equity attributable to owners of the Company | ||||||||||||||||||||||||||||||||||||||||||||||||
| Cash flow hedges | Hedging cost | Remeasurements of defined benefit pension plans | Total other components of equity | Non- controlling interests | Total equity | |||||||||||||||||||||||||||||||||||||||||||||
| As of April 1, 2025 | (64,852) | (7,967) | — | 2,351,915 | — | 6,935,084 | 895 | 6,935,979 | ||||||||||||||||||||||||||||||||||||||||||
| Net profit for the period | — | 216,081 | 202 | 216,283 | ||||||||||||||||||||||||||||||||||||||||||||||
| Other comprehensive income (loss) | 21,993 | 3,511 | 2,169 | 802,340 | 802,340 | 50 | 802,390 | |||||||||||||||||||||||||||||||||||||||||||
| Comprehensive income (loss) for the period | 21,993 | 3,511 | 2,169 | 802,340 | — | 1,018,421 | 252 | 1,018,673 | ||||||||||||||||||||||||||||||||||||||||||
| Transactions with owners: | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of new shares | — | 157 | 157 | |||||||||||||||||||||||||||||||||||||||||||||||
| Acquisition of treasury shares | — | (51,634) | (51,634) | |||||||||||||||||||||||||||||||||||||||||||||||
| Dividends | — | (312,524) | (312,524) | |||||||||||||||||||||||||||||||||||||||||||||||
| Transfers from other components of equity | (2,169) | (4,519) | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Share-based compensation | — | 53,439 | 53,439 | |||||||||||||||||||||||||||||||||||||||||||||||
| Exercise of share-based awards | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||
| Transfer to other comprehensive income associated with assets held for sale | 2,943 | (2,943) | — | — | ||||||||||||||||||||||||||||||||||||||||||||||
| Total transactions with owners | — | — | (2,169) | (1,575) | (2,943) | (310,562) | — | (310,562) | ||||||||||||||||||||||||||||||||||||||||||
| As of December 31, 2025 | (42,860) | (4,456) | — | 3,152,680 | (2,943) | 7,642,943 | 1,147 | 7,644,091 | ||||||||||||||||||||||||||||||||||||||||||
20
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(5) Condensed Interim Consolidated Statements of Cash Flows
| JPY (millions) | ||||||||||||||
| Nine-month Period Ended December 31, | ||||||||||||||
| 2024 | 2025 | |||||||||||||
| Cash flows from operating activities: | ||||||||||||||
| Net profit for the period | 211,241 | 216,283 | ||||||||||||
| Depreciation and amortization | 571,627 | 557,257 | ||||||||||||
| Impairment losses | 38,227 | 94,790 | ||||||||||||
| Equity-settled share-based compensation | 55,240 | 53,064 | ||||||||||||
| Loss on sales and disposal of property, plant and equipment | 3,059 | 1,274 | ||||||||||||
| Gain on divestment of business and subsidiaries | (6,376) | (17,929) | ||||||||||||
| Change in fair value of financial assets and liabilities associated with contingent consideration arrangements, net | 2,253 | 1,057 | ||||||||||||
| Finance (income) and expenses, net | 131,936 | 107,898 | ||||||||||||
| Share of loss of investments accounted for using the equity method | 3,199 | 1,816 | ||||||||||||
| Income tax expenses | 71,142 | 96,385 | ||||||||||||
| Changes in assets and liabilities: | ||||||||||||||
| Decrease (increase) in trade and other receivables | (45,105) | 27,350 | ||||||||||||
| Increase in inventories | (29,981) | (79,993) | ||||||||||||
| Decrease in trade and other payables | (17,448) | (7,949) | ||||||||||||
| Increase (decrease) in provisions | 39,885 | (5,261) | ||||||||||||
| Increase (decrease) in other financial liabilities | (9,596) | 14,759 | ||||||||||||
| Other, net | (82,164) | 14,544 | ||||||||||||
| Cash generated from operations | 937,140 | 1,075,345 | ||||||||||||
| Income taxes paid | (120,349) | (115,928) | ||||||||||||
| Tax refunds and interest on tax refunds received | 18,231 | 7,485 | ||||||||||||
| Net cash from operating activities | 835,023 | 966,903 | ||||||||||||
| Cash flows from investing activities: | ||||||||||||||
| Interest received | 13,324 | 12,866 | ||||||||||||
| Dividends received | 604 | 656 | ||||||||||||
| Acquisition of property, plant and equipment | (152,002) | (129,641) | ||||||||||||
| Proceeds from sales of property, plant and equipment | 46 | 6,400 | ||||||||||||
| Acquisition of intangible assets | (103,115) | (218,003) | ||||||||||||
| Acquisition of option to license | (31,784) | (2,622) | ||||||||||||
| Acquisition of investments | (95,364) | (15,157) | ||||||||||||
| Proceeds from sales and redemption of investments | 26,678 | 5,570 | ||||||||||||
| Acquisition of shares in associates | — | (623) | ||||||||||||
| Proceeds from sales of shares in associates | — | 880 | ||||||||||||
| Proceeds from sales of business, net of cash and cash equivalents divested | 9,590 | 32,810 | ||||||||||||
| Payments for the settlement of forward exchange contracts designated as net investment hedges | (13,933) | (1,536) | ||||||||||||
| Other, net | (1,423) | (2,724) | ||||||||||||
| Net cash used in investing activities | (347,379) | (311,124) | ||||||||||||
21
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
| JPY (millions) | ||||||||||||||
| Nine-month Period Ended December 31, | ||||||||||||||
| 2024 | 2025 | |||||||||||||
| Cash flows from financing activities: | ||||||||||||||
| Net decrease in short-term loans and commercial papers | (317,000) | (341,780) | ||||||||||||
| Proceeds from issuance of bonds and long-term loans | 1,024,460 | 526,060 | ||||||||||||
| Repayments of bonds and long-term loans | (784,079) | (125,408) | ||||||||||||
| Proceeds from the settlement of cross currency interest rate swaps related to bonds and loans | 46,880 | — | ||||||||||||
| Acquisition of treasury shares | (1,882) | (51,603) | ||||||||||||
| Interest paid | (78,106) | (82,082) | ||||||||||||
| Dividends paid | (292,760) | (303,114) | ||||||||||||
| Repayments of lease liabilities | (34,193) | (32,181) | ||||||||||||
| Other, net | (12,953) | (9,219) | ||||||||||||
| Net cash used in financing activities | (449,633) | (419,328) | ||||||||||||
| Net increase in cash and cash equivalents | 38,010 | 236,451 | ||||||||||||
| Cash and cash equivalents at the beginning of the year | 457,800 | 385,113 | ||||||||||||
| Effects of exchange rate changes on cash and cash equivalents | (1,685) | 33,373 | ||||||||||||
| Cash and cash equivalents at the end of the period | 494,126 | 654,937 | ||||||||||||
22
Takeda Pharmaceutical Company Limited (4502)
Earnings Report (Kessan Tanshin) for the Nine-month
Period Ended December 31, 2025 (Consolidated)
(6) Notes to Condensed Interim Consolidated Financial Statements
(Significant Uncertainty Regarding Going Concern Assumption)
Not applicable.
(Material Accounting Policies)
Material accounting policies adopted for the condensed interim consolidated financial statements are the same as those adopted for the consolidated financial statements as of and for the fiscal year ended March 31, 2025.
Takeda calculated income tax expenses for the nine-month period ended December 31, 2025, based on the estimated average annual effective tax rate.
(Operating Segment Information)
Takeda comprises a single operating segment and is engaged in the research, development, manufacturing, marketing and out-licensing of pharmaceutical products. This is consistent with how the financial information is viewed in allocating resources, measuring performance, and forecasting future periods by the CEO who is Takeda’s Chief Operating Decision Maker.
(Significant Subsequent Events)
Not applicable.
23
Exhibit 99.1
| FINANCIAL APPENDIX | ||
Definition of Non-IFRS Measures | ||||||||
Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations | A-1 | |||||||
Reconciliations and Other Financial Information | ||||||||
FY2025 Q3 YTD Reported Results with CER % Change | A-4 | |||||||
FY2025 Q3 (Oct-Dec) Reported Results with CER % Change | A-5 | |||||||
FY2025 Q3 YTD Core Results with CER % Change | A-6 | |||||||
FY2025 Q3 (Oct-Dec) Core Results with CER % Change | A-7 | |||||||
FY2025 Q3 YTD Reconciliation from Reported to Core | A-8 | |||||||
FY2025 Q3 (Oct-Dec) Reconciliation from Reported to Core | A-9 | |||||||
FY2024 Q3 YTD Reconciliation from Reported to Core | A-10 | |||||||
FY2024 Q3 (Oct-Dec) Reconciliation from Reported to Core | A-11 | |||||||
FY2025 Q3 YTD Adjusted Free Cash Flow | A-12 | |||||||
FY2025 Q3 YTD Adjusted Net Debt to Adjusted EBITDA | A-13 | |||||||
FY2024 Adjusted Net Debt to Adjusted EBITDA | A-14 | |||||||
FY2025 Q3 YTD Net Profit to Adjusted EBITDA Bridge | A-15 | |||||||
FY2025 Q3 YTD Net Profit to Adjusted EBITDA LTM Bridge | A-16 | |||||||
FY2025 Q3 YTD CAPEX, Depreciation and Amortization and Impairment Losses | A-17 | |||||||
FY2025 Full Year Detailed Forecast | A-18 | |||||||
FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast | A-19 | |||||||
FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast | A-20 | |||||||
Important Notice | ||||||||
Important Notice, Forward-Looking Statements, Financial Information and Non-IFRS Measures, and Medical Information | A-21 | |||||||
Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations | ||
Core Financial Measures
Takeda’s Core Financial Measures, particularly Core Revenue, Core Operating Profit, Core Net Profit for the Year attributable to owners of the Company and Core EPS, exclude revenue from divestments, amortization and impairment losses on intangible assets associated with products (including in-process R&D) and other impacts unrelated to the underlying trends and business performance of Takeda’s core operations, such as non-recurring items, purchase accounting effects and transaction related costs. Core Revenue represents revenue adjusted to exclude revenue items unrelated to the underlying trends and business performance of Takeda’s core operations (primarily revenue or related adjustments associated with divestments and liquidations). Core Operating Profit represents operating profit adjusted to exclude other operating expenses and income, amortization and impairment losses on intangible assets associated with products (including in-process R&D) and non-cash items or items unrelated to the underlying trends and business performance of Takeda’s core operations. Core Net Profit for the Year attributable to owners of the Company represents net profit for the year attributable to owners of the Company, adjusted to eliminate the impact of items excluded in the calculation of Core Operating Profit and other non-operating items (e.g. amongst other items, fair value adjustments and the imputed financial charge related to contingent consideration) that are unusual, non-recurring in nature or unrelated to the underlying trends and business performance of Takeda’s ongoing operations and the tax effect of each of the adjustments. Core EPS is calculated by dividing Core Net Profit for the Year attributable to owners of the Company by the average outstanding shares (excluding treasury shares) of the reporting periods presented.
Takeda presents its Core Financial Measures because Takeda believes that these measures are useful to understanding its business without the effect of items that Takeda considers to be unrelated to the underlying trends and business performance of its core operations, including items (i) which may vary significantly from year-to-year or may not occur in each year or (ii) whose recognition Takeda believes is largely uncorrelated to trends in the underlying performance of our core business. Takeda believes that similar measures are frequently used by other companies in its industry and that providing these measures helps investors evaluate Takeda’s performance against not only its performance in prior years but on a similar basis as its competitors. Takeda also presents Core Financial Measures because these measures are used by Takeda for budgetary planning and compensation purposes (i.e., certain targets for the purposes of Takeda’s Short-Term Incentive and Long-Term Incentive compensation programs, including incentive compensation of the CEO and CFO, are set in relation to the results of Takeda’s Core Financial Measures).
Constant Exchange Rate (“CER”) Change
CER Change eliminates the effect of foreign exchange rates from year-over-year comparisons by translating financial results in accordance with IFRS or Core (non-IFRS) financial measures for the current period using corresponding exchange rates in the same period of the previous fiscal year, provided, however, that the results of operations of subsidiaries in countries experiencing hyperinflation, and for which IAS 29, Financial Reporting in Hyperinflationary Economies, is applied, are not adjusted for CER Change, and instead are calculated in accordance with IAS 29.
Takeda presents CER change because we believe that this measure is useful to investors to better understand the effect of exchange rates on our business and to understand how our results of operations might have changed from year to year without the effect of fluctuations in exchange rates. These are the primary ways in which our management uses these measures to evaluate our results of operations. We also believe that this is a useful measure for investors as similar performance measures are frequently used by securities analysts, investors and other interested parties in the evaluation of the results of operations of other companies in our industry (many of whom similarly present measures that adjust for the effect of exchange rates).
The usefulness of this presentation has significant limitations including but not limited to, that while CER change is calculated using the same exchange rates used to calculate financial results as presented under IFRS for the previous fiscal year, this does not necessarily mean that the transactions entered into during the relevant fiscal year could have been entered into or would have been recorded at the same exchange rates. Moreover, other companies in our industry using similarly titled measures may define and calculate those measures differently than we do and therefore such measures may not be directly comparable. Accordingly, CER change should not be considered in isolation and is not, and should not be viewed as, a substitute for change in financial results as prepared and presented in accordance with IFRS.
A-1
Free Cash Flow and Adjusted Free Cash Flow
Takeda defines Free Cash Flow as cash flows from operating activities less acquisition of property, plant and equipment (“PP&E”). Takeda defines Adjusted Free Cash Flow as cash flows from operating activities, subtracting payments for acquisition of PP&E, intangible assets, investments (excluding debt investments classified as Level 1 in the fair value hierarchy), shares in associates and businesses, net of cash and cash equivalents acquired and other transactional payments deemed related or similar in substance thereto as well as adding proceeds from sales of PP&E, sales and redemption of investments (excluding debt investments classified as Level 1 in the fair value hierarchy), sales of shares in associates and sales of businesses, net of cash and cash equivalents divested and further adjusting for the movement of any other cash that is not available to Takeda’s immediate or general business use.
Takeda presents Free Cash Flow and Adjusted Free Cash Flow because Takeda believes that these measures are useful to investors as similar measures of liquidity are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Adjusted Free Cash Flow is also used by our management to evaluate our liquidity and our cash flows, particularly as they relate to our ability to meet our liquidity requirements and to support our capital allocation policies. Takeda also believes that Free Cash Flow and Adjusted Free Cash Flow are helpful to investors in understanding how our strategic acquisitions and divestitures of businesses contribute to our cash flows and liquidity.
The usefulness of Free Cash Flow and Adjusted Free Cash Flow to investors has significant limitations including, but not limited to, (i) they may not be comparable to similarly titled measures used by other companies, including those in our industry, (ii) they do not reflect the effect of our current and future contractual and other commitments requiring the use or allocation of capital and (iii) the addition of proceeds from sales and redemption of investments and the proceeds from sales of business, net of cash and cash equivalents divested do not represent cash received from our core ongoing operations. Free Cash Flow and Adjusted Free Cash Flow should not be considered in isolation and are not, and should not be viewed as, substitutes for cash flows from operating activities or any other measure of liquidity presented in accordance with IFRS. The most directly comparable measure under IFRS for Free Cash Flow and Adjusted Free Cash Flow is net cash from operating activities.
EBITDA and Adjusted EBITDA
Takeda defines EBITDA as consolidated net profit before income tax expenses, depreciation and amortization and net interest expense. Takeda defines Adjusted EBITDA as EBITDA further adjusted to exclude impairment losses, other operating income and expenses (excluding depreciation and amortization, as well as impairment losses), finance income and expenses (excluding net interest expense), our share of profit or loss of investments accounted for using the equity method, other non-cash items such as non-cash equity-based compensation expense, and other items that management believes are unrelated to our core operations, including EBITDA from divested products, purchase accounting effects and transaction related costs.
Takeda presents EBITDA and Adjusted EBITDA because Takeda believes that these measures are useful to investors as they are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Primarily, Adjusted EBITDA is used by Takeda for the purposes of monitoring its financial leverage. Takeda further believes that Adjusted EBITDA is helpful to investors in identifying trends in its business that could otherwise be obscured by certain items unrelated to ongoing operations because they are highly variable, difficult to predict, may substantially impact our results of operations and may limit the ability to evaluate our performance from one period to another on a consistent basis.
The usefulness of EBITDA and Adjusted EBITDA to investors has significant limitations including, but not limited to, (i) they may not be comparable to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) they exclude financial information and events, such as the effects of an acquisition, or amortization of intangible assets, that some may consider important in evaluating Takeda’s performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future and (iv) they may not include all items which investors may consider important to an understanding of our results of operations, or may not exclude all items which investors may not consider important for such understanding. EBITDA and Adjusted EBITDA should not be considered in isolation and are not, and should not be viewed as, substitutes for operating income, net profit for the year or any other measure of performance presented in accordance with IFRS. The most closely comparable measure presented in accordance with IFRS is net profit for the year.
A-2
Net Debt and Adjusted Net Debt
Takeda defines Net Debt as the book value of bonds and loans on consolidated statements of financial position adjusted only for cash and cash equivalents and Adjusted Net Debt first by calculating the sum of the current and non-current portions of bonds and loans as shown on our consolidated statement of financial position, which is then adjusted to reflect (i) the use of prior 12-month average exchange rates for non-JPY debt outstanding at the beginning of the period and the use of relevant spot rates for new non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period, which reflects the methodology our management uses to monitor our leverage, and (ii) the “equity credit” applied to Takeda’s “hybrid” subordinated indebtedness by S&P Global Rating Japan in recognition of the equity-like features of those instruments pursuant to such agency’s ratings methodology. To calculate Adjusted Net Debt, Takeda deducts from this figure cash and cash equivalents, excluding cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.
Takeda presents Net Debt and Adjusted Net Debt because Takeda believes that these measures are useful to investors in that our management uses it to monitor and evaluate our indebtedness, net of cash and cash equivalents and, in conjunction with Adjusted EBITDA, to monitor our financial leverage (for the avoidance of doubt, Adjusted Net Debt and the ratio of Adjusted Net Debt to Adjusted EBITDA are not intended to be indicators of Takeda’s liquidity). Takeda also believes that similar measures of indebtedness are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Particularly following the acquisition of Shire, investors, analysts and, in particular, ratings agencies, have closely monitored Takeda’s leverage, as represented by the ratio of its Adjusted Net Debt to Adjusted EBITDA. In light of the weight given by ratings agencies in particular to this ratio, Takeda believes that such information is useful to investors to help understand not only Takeda’s financial leverage, but also how ratings agencies evaluate the level of financial leverage in evaluating Takeda’s quality of credit. Accordingly, as described below, Takeda includes an adjustment to its Adjusted Net Debt to reflect the “equity credit” afforded to certain of its subordinated indebtedness by ratings agencies (such indebtedness does not qualify for treatment as equity under IFRS).
The usefulness of Adjusted Net Debt to investors has significant limitations including, but not limited to, (i) it may not be comparable to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) it does not reflect the amounts of interest payments to be paid on Takeda’s indebtedness, (iii) it does not reflect any restrictions on Takeda’s ability to prepay or redeem any of our indebtedness, (iv) it does not reflect any fees, costs or other expenses that Takeda may incur in converting cash equivalents to cash, in converting cash from one currency into another or in moving cash within our consolidated group, (v) it applies to gross debt an adjustment for average foreign exchange rates which, although consistent with Takeda’s financing agreements, does not reflect the actual rates at which Takeda would be able to convert one currency into another and (vi) it reflects an equity credit despite the fact that Takeda’s subordinated bonds are not eligible for equity treatment under IFRS, although Takeda believes this adjustment to be reasonable and useful to investors. Adjusted Net Debt should not be considered in isolation and is not, and should not be viewed as, a substitute for bonds and loans or any other measure of indebtedness presented in accordance with IFRS. The most directly comparable measures under IFRS for Net Debt is bonds and loans.
U.S. Dollar Convenience Translations
In the Financial Appendix, certain amounts presented in Japanese yen have been translated to U.S. dollars solely for the convenience of the reader at an exchange rate of 1USD = 156.80 JPY, the Noon Buying Rate certified by the Federal Reserve Bank of New York on December 31, 2025. The rate and methodologies used for the convenience translations differ from the currency exchange rates and translation methodologies under IFRS used for the preparation of the condensed interim consolidated financial statements. The translation should not be construed as a representation that the Japanese yen amounts could be converted into U.S. dollars at this or any other rate.
A-3
FY2025 Q3 YTD Reported Results with CER % Change | ||
(Billion JPY, except EPS) | FY2024 Q3 YTD | FY2025 Q3 YTD | AER | CER | (Million USD, except EPS) FY2025 Q3 YTD Convenience USD Translation | ||||||||||||||||||||||||
JPY Change | % Change | % Change | |||||||||||||||||||||||||||
| Revenue | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | 21,755 | |||||||||||||||||||||
| Cost of sales | (1,198.1) | (1,165.9) | 32.3 | 2.7 | % | 2.4 | % | (7,435) | |||||||||||||||||||||
| Gross profit | 2,330.0 | 2,245.3 | (84.7) | (3.6) | % | (3.0) | % | 14,319 | |||||||||||||||||||||
| Margin | 66.0 | % | 65.8 | % | (0.2) | pp | (0.2) | pp | 65.8 | % | |||||||||||||||||||
| SG&A expenses | (808.9) | (792.2) | 16.7 | 2.1 | % | 1.3 | % | (5,052) | |||||||||||||||||||||
| R&D expenses | (514.2) | (480.6) | 33.6 | 6.5 | % | 5.1 | % | (3,065) | |||||||||||||||||||||
| Amortization of intangible assets associated with products | (411.7) | (396.9) | 14.7 | 3.6 | % | 2.3 | % | (2,531) | |||||||||||||||||||||
Impairment losses on intangible assets associated with products* | (28.5) | (81.8) | (53.3) | (186.9) | % | (182.2) | % | (522) | |||||||||||||||||||||
| Other operating income | 16.2 | 22.7 | 6.4 | 39.7 | % | 40.3 | % | 145 | |||||||||||||||||||||
| Other operating expenses | (165.4) | (94.0) | 71.4 | 43.2 | % | 42.8 | % | (600) | |||||||||||||||||||||
| Operating profit | 417.5 | 422.4 | 4.9 | 1.2 | % | 0.1 | % | 2,694 | |||||||||||||||||||||
| Margin | 11.8 | % | 12.4 | % | 0.5 | pp | 0.4 | pp | 12.4 | % | |||||||||||||||||||
| Finance income | 27.8 | 206.0 | 178.2 | 641.0 | % | 642.1 | % | 1,314 | |||||||||||||||||||||
| Finance expenses | (159.7) | (313.9) | (154.2) | (96.5) | % | (99.6) | % | (2,002) | |||||||||||||||||||||
Share of profit (loss) of investments accounted for using the equity method | (3.2) | (1.8) | 1.4 | 43.2 | % | 53.5 | % | (12) | |||||||||||||||||||||
| Profit before tax | 282.4 | 312.7 | 30.3 | 10.7 | % | 7.7 | % | 1,994 | |||||||||||||||||||||
Income tax (expenses) benefit | (71.1) | (96.4) | (25.2) | (35.5) | % | (26.4) | % | (615) | |||||||||||||||||||||
| Net profit for the period | 211.2 | 216.3 | 5.0 | 2.4 | % | 1.4 | % | 1,379 | |||||||||||||||||||||
| Non-controlling interests | (0.2) | (0.2) | (0.0) | (27.3) | % | (35.9) | % | (1) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 211.1 | 216.1 | 5.0 | 2.4 | % | 1.4 | % | 1,378 | |||||||||||||||||||||
| Basic EPS (JPY or USD) | 133.71 | 137.31 | 3.60 | 2.7 | % | 1.7 | % | 0.88 | |||||||||||||||||||||
* Includes in-process R&D
The amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of the “Constant Exchange Rate change”.
% change is presented as positive when favorable to profits, and negative when unfavorable to profits.
A-4
| FY2025 Q3 (Oct-Dec) Reported Results with CER % Change | ||
| (Billion JPY, except EPS) | FY2024 Q3 (Oct-Dec) | FY2025 Q3 (Oct-Dec) | AER | CER | (Million USD, except EPS) FY2025 Q3 (Oct-Dec) Convenience USD Translation | ||||||||||||||||||||||||
JPY Change | % Change | % Change | |||||||||||||||||||||||||||
| Revenue | 1,144.1 | 1,191.7 | 47.6 | 4.2 | % | (0.6) | % | 7,600 | |||||||||||||||||||||
| Cost of sales | (416.9) | (401.1) | 15.7 | 3.8 | % | 8.5 | % | (2,558) | |||||||||||||||||||||
| Gross profit | 727.3 | 790.6 | 63.3 | 8.7 | % | 3.9 | % | 5,042 | |||||||||||||||||||||
| Margin | 63.6 | % | 66.3 | % | 2.8 | pp | 2.9 | pp | 66.3 | % | |||||||||||||||||||
| SG&A expenses | (270.6) | (282.8) | (12.2) | (4.5) | % | (0.1) | % | (1,803) | |||||||||||||||||||||
| R&D expenses | (170.2) | (175.2) | (5.0) | (3.0) | % | 0.2 | % | (1,118) | |||||||||||||||||||||
| Amortization of intangible assets associated with products | (134.2) | (136.2) | (2.0) | (1.5) | % | 2.7 | % | (868) | |||||||||||||||||||||
Impairment losses on intangible assets associated with products* | (0.7) | (5.8) | (5.0) | (671.6) | % | (642.6) | % | (37) | |||||||||||||||||||||
| Other operating income | 2.4 | (0.9) | (3.2) | ― | ― | (5) | |||||||||||||||||||||||
| Other operating expenses | (87.0) | (20.9) | 66.0 | 75.9 | % | 77.0 | % | (134) | |||||||||||||||||||||
| Operating profit | 66.9 | 168.8 | 101.9 | 152.2 | % | 136.7 | % | 1,077 | |||||||||||||||||||||
| Margin | 5.9 | % | 14.2 | % | 8.3 | pp | 8.1 | pp | 14.2 | % | |||||||||||||||||||
| Finance income | 25.2 | 88.3 | 63.1 | 250.5 | % | 250.1 | % | 563 | |||||||||||||||||||||
| Finance expenses | (63.8) | (124.1) | (60.3) | (94.6) | % | (100.0) | % | (791) | |||||||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | (2.0) | 0.8 | 2.8 | ― | ― | 5 | |||||||||||||||||||||||
| Profit before tax | 26.4 | 133.9 | 107.5 | 406.9 | % | 354.4 | % | 854 | |||||||||||||||||||||
Income tax (expenses) benefit | (2.6) | (30.1) | (27.6) | (1,071.4) | % | (913.5) | % | (192) | |||||||||||||||||||||
| Net profit for the period | 23.8 | 103.7 | 79.9 | 335.2 | % | 294.1 | % | 662 | |||||||||||||||||||||
| Non-controlling interests | (0.0) | (0.1) | (0.0) | (103.1) | % | (114.5) | % | (1) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 23.8 | 103.6 | 79.9 | 335.7 | % | 294.4 | % | 661 | |||||||||||||||||||||
Basic EPS (JPY or USD) | 15.01 | 65.61 | 50.60 | 337.2 | % | 295.8 | % | 0.42 | |||||||||||||||||||||
* Includes in-process R&D
The amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of the “Constant Exchange Rate change”.
% change is presented as positive when favorable to profits, and negative when unfavorable to profits.
A-5
| FY2025 Q3 YTD Core Results with CER % Change | ||
(Billion JPY, except EPS) | FY2024 Q3 YTD | FY2025 Q3 YTD | AER | CER | (Million USD, except EPS) FY2025 Q3 YTD Convenience USD Translation | ||||||||||||||||||||||||
JPY Change | % Change | % Change | |||||||||||||||||||||||||||
| Revenue | 3,528.2 | 3,411.2 | (117.0) | (3.3) | % | (2.8) | % | 21,755 | |||||||||||||||||||||
| Cost of sales | (1,198.3) | (1,166.4) | 32.0 | 2.7 | % | 2.4 | % | (7,438) | |||||||||||||||||||||
| Gross profit | 2,329.8 | 2,244.8 | (85.0) | (3.6) | % | (3.0) | % | 14,316 | |||||||||||||||||||||
| Margin | 66.0 | % | 65.8 | % | (0.2) | pp | (0.2) | pp | 65.8 | % | |||||||||||||||||||
| SG&A expenses | (809.2) | (792.5) | 16.7 | 2.1 | % | 1.3 | % | (5,054) | |||||||||||||||||||||
| R&D expenses | (514.3) | (480.7) | 33.6 | 6.5 | % | 5.1 | % | (3,066) | |||||||||||||||||||||
| Operating profit | 1,006.3 | 971.6 | (34.7) | (3.4) | % | (3.4) | % | 6,196 | |||||||||||||||||||||
| Margin | 28.5 | % | 28.5 | % | (0.0) | pp | (0.2) | pp | 28.5 | % | |||||||||||||||||||
| Finance income | 21.4 | 205.9 | 184.4 | 859.9 | % | 861.2 | % | 1,313 | |||||||||||||||||||||
| Finance expenses | (127.6) | (304.8) | (177.2) | (138.9) | % | (142.7) | % | (1,944) | |||||||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | 1.5 | 0.2 | (1.3) | (86.1) | % | (61.1) | % | 1 | |||||||||||||||||||||
| Profit before tax | 901.6 | 872.9 | (28.8) | (3.2) | % | (3.6) | % | 5,567 | |||||||||||||||||||||
| Income tax (expenses) benefit | (202.6) | (199.1) | 3.5 | 1.7 | % | 4.5 | % | (1,270) | |||||||||||||||||||||
| Net profit for the period | 699.1 | 673.8 | (25.3) | (3.6) | % | (3.4) | % | 4,297 | |||||||||||||||||||||
| Non-controlling interests | (0.2) | (0.2) | (0.0) | (27.3) | % | (35.9) | % | (1) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 698.9 | 673.6 | (25.3) | (3.6) | % | (3.4) | % | 4,296 | |||||||||||||||||||||
Basic EPS (JPY or USD) | 443 | 428 | (15) | (3.3) | % | (3.1) | % | 2.73 | |||||||||||||||||||||
The amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of the “Constant Exchange Rate change”.
% change is presented as positive when favorable to profits, and negative when unfavorable to profits.
A-6
FY2025 Q3 (Oct-Dec) Core Results with CER % Change | ||
| (Billion JPY, except EPS) | FY2024 Q3 (Oct-Dec) | FY2025 Q3 (Oct-Dec) | AER | CER | (Million USD, except EPS) FY2025 Q3 (Oct-Dec) Convenience USD Translation | ||||||||||||||||||||||||
JPY Change | % Change | % Change | |||||||||||||||||||||||||||
| Revenue | 1,144.1 | 1,191.7 | 47.6 | 4.2 | % | (0.6) | % | 7,600 | |||||||||||||||||||||
| Cost of sales | (416.9) | (401.2) | 15.7 | 3.8 | % | 8.5 | % | (2,559) | |||||||||||||||||||||
| Gross profit | 727.2 | 790.5 | 63.3 | 8.7 | % | 3.9 | % | 5,041 | |||||||||||||||||||||
| Margin | 63.6 | % | 66.3 | % | 2.8 | pp | 2.9 | pp | 66.3 | % | |||||||||||||||||||
| SG&A expenses | (270.7) | (282.8) | (12.2) | (4.5) | % | (0.1) | % | (1,804) | |||||||||||||||||||||
| R&D expenses | (170.2) | (175.2) | (5.0) | (2.9) | % | 0.2 | % | (1,118) | |||||||||||||||||||||
| Operating profit | 286.4 | 332.4 | 46.1 | 16.1 | % | 10.1 | % | 2,120 | |||||||||||||||||||||
| Margin | 25.0 | % | 27.9 | % | 2.9 | pp | 2.7 | pp | 27.9 | % | |||||||||||||||||||
| Finance income | 23.8 | 88.7 | 64.9 | 273.4 | % | 272.9 | % | 566 | |||||||||||||||||||||
| Finance expenses | (56.6) | (120.5) | (63.9) | (112.9) | % | (119.1) | % | (769) | |||||||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | (0.1) | 0.8 | 0.9 | ― | ― | 5 | |||||||||||||||||||||||
| Profit before tax | 253.4 | 301.4 | 48.0 | 19.0 | % | 10.7 | % | 1,922 | |||||||||||||||||||||
| Income tax (expenses) benefit | (43.5) | (66.3) | (22.8) | (52.5) | % | (38.1) | % | (423) | |||||||||||||||||||||
| Net profit for the period | 209.9 | 235.1 | 25.2 | 12.0 | % | 5.1 | % | 1,499 | |||||||||||||||||||||
| Non-controlling interests | (0.0) | (0.1) | (0.0) | (103.1) | % | (114.5) | % | (1) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 209.8 | 235.0 | 25.1 | 12.0 | % | 5.1 | % | 1,498 | |||||||||||||||||||||
Basic EPS (JPY or USD) | 132 | 149 | 16 | 12.4 | % | 5.4 | % | 0.95 | |||||||||||||||||||||
The amount of change and percentage change based on Actual Exchange Rates are presented in “AER” (which is presented in accordance with IFRS) and percentage change based on Constant Exchange Rate (which is a non-IFRS measure) is presented in “CER”. Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of the “Constant Exchange Rate change”.
% change is presented as positive when favorable to profits, and negative when unfavorable to profits.
A-7
FY2025 Q3 YTD Reconciliation from Reported to Core | ||
| (Billion JPY, except EPS and number of shares) | Reported | Reported to Core adjustments | Core | |||||||||||||||||
| Amortization of intangible assets | Impairment of intangible assets | Other operating income/ expenses | Others | |||||||||||||||||
| Revenue | 3,411.2 | 3,411.2 | ||||||||||||||||||
| Cost of sales | (1,165.9) | (0.5) | (1,166.4) | |||||||||||||||||
| Gross profit | 2,245.3 | (0.5) | 2,244.8 | |||||||||||||||||
| SG&A expenses | (792.2) | (0.3) | (792.5) | |||||||||||||||||
| R&D expenses | (480.6) | (0.1) | (480.7) | |||||||||||||||||
| Amortization of intangible assets associated with products | (396.9) | 396.9 | — | |||||||||||||||||
Impairment losses on intangible assets associated with products* | (81.8) | 81.8 | — | |||||||||||||||||
| Other operating income | 22.7 | (22.7) | — | |||||||||||||||||
| Other operating expenses | (94.0) | 94.0 | — | |||||||||||||||||
| Operating profit | 422.4 | 396.9 | 81.8 | 71.4 | (0.9) | 971.6 | ||||||||||||||
| Margin | 12.4 | % | 28.5 | % | ||||||||||||||||
| Finance income and (expenses), net | (107.9) | 8.9 | (98.9) | |||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | (1.8) | 2.0 | 0.2 | |||||||||||||||||
| Profit before tax | 312.7 | 396.9 | 81.8 | 71.4 | 10.1 | 872.9 | ||||||||||||||
| Income tax (expenses) benefit | (96.4) | (79.9) | (6.2) | (12.8) | (3.8) | (199.1) | ||||||||||||||
| Non-controlling interests | (0.2) | (0.2) | ||||||||||||||||||
| Net profit attributable to owners of the Company | 216.1 | 317.0 | 75.6 | 58.6 | 6.3 | 673.6 | ||||||||||||||
| Basic EPS (JPY) | 137 | 428 | ||||||||||||||||||
| Number of shares (millions) | 1,574 | 1,574 | ||||||||||||||||||
* Includes in-process R&D.
A-8
FY2025 Q3 (Oct-Dec) Reconciliation from Reported to Core | ||
| (Billion JPY, except EPS and number of shares) | Reported | Reported to Core adjustments | Core | |||||||||||||||||
| Amortization of intangible assets | Impairment of intangible assets | Other operating income/ expenses | Others | |||||||||||||||||
| Revenue | 1,191.7 | 1,191.7 | ||||||||||||||||||
| Cost of sales | (401.1) | (0.1) | (401.2) | |||||||||||||||||
| Gross profit | 790.6 | (0.1) | 790.5 | |||||||||||||||||
| SG&A expenses | (282.8) | (0.1) | (282.8) | |||||||||||||||||
| R&D expenses | (175.2) | (0.0) | (175.2) | |||||||||||||||||
| Amortization of intangible assets associated with products | (136.2) | 136.2 | — | |||||||||||||||||
Impairment losses on intangible assets associated with products* | (5.8) | 5.8 | — | |||||||||||||||||
| Other operating income | (0.9) | 0.9 | — | |||||||||||||||||
| Other operating expenses | (20.9) | 20.9 | — | |||||||||||||||||
| Operating profit | 168.8 | 136.2 | 5.8 | 21.8 | (0.1) | 332.4 | ||||||||||||||
| Margin | 14.2 | % | 27.9 | % | ||||||||||||||||
| Finance income and (expenses), net | (35.8) | 3.9 | (31.8) | |||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | 0.8 | (0.0) | 0.8 | |||||||||||||||||
| Profit before tax | 133.9 | 136.2 | 5.8 | 21.8 | 3.8 | 301.4 | ||||||||||||||
| Income tax (expenses) benefit | (30.1) | (27.5) | (1.2) | (5.1) | (2.4) | (66.3) | ||||||||||||||
| Non-controlling interests | (0.1) | (0.1) | ||||||||||||||||||
| Net profit attributable to owners of the Company | 103.6 | 108.7 | 4.5 | 16.7 | 1.4 | 235.0 | ||||||||||||||
| Basic EPS (JPY) | 66 | 149 | ||||||||||||||||||
| Number of shares (millions) | 1,580 | 1,580 | ||||||||||||||||||
* Includes in-process R&D.
A-9
FY2024 Q3 YTD Reconciliation from Reported to Core | ||
| (Billion JPY, except EPS and number of shares) | Reported | Reported to Core adjustments | Core | ||||||||||||||||||||
| Amortization of intangible assets | Impairment of intangible assets | Teva JV related adjustment*2 | Other operating income/ expenses | Others | |||||||||||||||||||
| Revenue | 3,528.2 | 3,528.2 | |||||||||||||||||||||
| Cost of sales | (1,198.1) | (0.2) | (1,198.3) | ||||||||||||||||||||
| Gross profit | 2,330.0 | (0.2) | 2,329.8 | ||||||||||||||||||||
| SG&A expenses | (808.9) | (0.3) | (809.2) | ||||||||||||||||||||
| R&D expenses | (514.2) | (0.1) | (514.3) | ||||||||||||||||||||
| Amortization of intangible assets associated with products | (411.7) | 411.7 | — | ||||||||||||||||||||
Impairment losses on intangible assets associated with products*1 | (28.5) | 28.5 | — | ||||||||||||||||||||
| Other operating income | 16.2 | (16.2) | — | ||||||||||||||||||||
| Other operating expenses | (165.4) | 165.4 | — | ||||||||||||||||||||
| Operating profit | 417.5 | 411.7 | 28.5 | 149.2 | (0.6) | 1,006.3 | |||||||||||||||||
| Margin | 11.8 | % | 28.5 | % | |||||||||||||||||||
| Finance income and (expenses), net | (131.9) | 19.4 | 6.4 | (106.2) | |||||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | (3.2) | 4.7 | 1.5 | ||||||||||||||||||||
| Profit before tax | 282.4 | 411.7 | 28.5 | 19.4 | 149.2 | 10.5 | 901.6 | ||||||||||||||||
| Income tax (expenses) benefit | (71.1) | (86.2) | (8.2) | (5.9) | (36.5) | 5.3 | (202.6) | ||||||||||||||||
| Non-controlling interests | (0.2) | (0.2) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 211.1 | 325.5 | 20.3 | 13.4 | 112.7 | 15.9 | 698.9 | ||||||||||||||||
| Basic EPS (JPY) | 134 | 443 | |||||||||||||||||||||
| Number of shares (millions) | 1,579 | 1,579 | |||||||||||||||||||||
*1 Includes in-process R&D.
*2 An impairment loss of JPY 19.4 billion recorded as a result of the classification of Teva Takeda Pharma Ltd. shares as assets held for sale for the nine-month period ended December 31, 2024.
A-10
FY2024 Q3 (Oct-Dec) Reconciliation from Reported to Core | ||
| (Billion JPY, except EPS and number of shares) | Reported | Reported to Core adjustments | Core | ||||||||||||||||||||
| Amortization of intangible assets | Impairment of intangible assets | Teva JV related adjustment*2 | Other operating income/ expenses | Others | |||||||||||||||||||
| Revenue | 1,144.1 | 1,144.1 | |||||||||||||||||||||
| Cost of sales | (416.9) | (0.0) | (416.9) | ||||||||||||||||||||
| Gross profit | 727.3 | (0.0) | 727.2 | ||||||||||||||||||||
| SG&A expenses | (270.6) | (0.1) | (270.7) | ||||||||||||||||||||
| R&D expenses | (170.2) | (0.0) | (170.2) | ||||||||||||||||||||
| Amortization of intangible assets associated with products | (134.2) | 134.2 | — | ||||||||||||||||||||
Impairment losses on intangible assets associated with products*1 | (0.7) | 0.7 | — | ||||||||||||||||||||
| Other operating income | 2.4 | (2.4) | — | ||||||||||||||||||||
| Other operating expenses | (87.0) | 87.0 | — | ||||||||||||||||||||
| Operating profit | 66.9 | 134.2 | 0.7 | 84.6 | (0.1) | 286.4 | |||||||||||||||||
| Margin | 5.9 | % | 25.0 | % | |||||||||||||||||||
| Finance income and (expenses), net | (38.6) | 1.0 | 4.7 | (32.9) | |||||||||||||||||||
| Share of profit (loss) of investments accounted for using the equity method | (2.0) | 1.8 | (0.1) | ||||||||||||||||||||
| Profit before tax | 26.4 | 134.2 | 0.7 | 1.0 | 84.6 | 6.4 | 253.4 | ||||||||||||||||
| Income tax (expenses) benefit | (2.6) | (28.1) | (0.2) | (0.3) | (21.8) | 9.5 | (43.5) | ||||||||||||||||
| Non-controlling interests | (0.0) | (0.0) | |||||||||||||||||||||
| Net profit attributable to owners of the Company | 23.8 | 106.1 | 0.5 | 0.7 | 62.8 | 15.9 | 209.8 | ||||||||||||||||
| Basic EPS (JPY) | 15 | 132 | |||||||||||||||||||||
| Number of shares (millions) | 1,585 | 1,585 | |||||||||||||||||||||
*1 Includes in-process R&D.
*2 An impairment loss of JPY 1.0 billion recorded as a result of the classification of Teva Takeda Pharma Ltd. shares as assets held for sale for the quarter ended December 31, 2024.
A-11
FY2025 Q3 YTD Adjusted Free Cash Flow | ||||||||||||||||||||
| (Billion JPY) | FY2024 Q3 YTD | FY2025 Q3 YTD | JPY Change | % Change | (Million USD) FY2025 Q3 YTD Convenience USD Translation | |||||||||||||||
| Net profit | 211.2 | 216.3 | 5.0 | 2.4 | % | 1,379 | ||||||||||||||
| Depreciation, amortization and impairment losses | 609.9 | 652.0 | 42.2 | 4,158 | ||||||||||||||||
| Decrease (increase) in trade working capital | (92.5) | (60.6) | 31.9 | (386) | ||||||||||||||||
| Income taxes paid | (120.3) | (115.9) | 4.4 | (739) | ||||||||||||||||
| Tax refunds and interest on tax refunds received | 18.2 | 7.5 | (10.7) | 48 | ||||||||||||||||
| Other | 208.6 | 267.6 | 59.0 | 1,707 | ||||||||||||||||
| Net cash from operating activities (Operating Cash Flow) | 835.0 | 966.9 | 131.9 | 15.8 | % | 6,166 | ||||||||||||||
| Acquisition of PP&E | (152.0) | (129.6) | 22.4 | (827) | ||||||||||||||||
Free Cash Flow*1 | 683.0 | 837.3 | 154.2 | 22.6 | % | 5,340 | ||||||||||||||
Adjustment for cash temporarily held by Takeda on behalf of third parties*2 | (0.9) | (20.6) | (19.7) | (131) | ||||||||||||||||
| Proceeds from sales of PP&E | 0.0 | 6.4 | 6.4 | 41 | ||||||||||||||||
Acquisition of intangible assets*3 | (103.1) | (218.0) | (114.9) | (1,390) | ||||||||||||||||
| Acquisition of option to license | (31.8) | (2.6) | 29.2 | (17) | ||||||||||||||||
Acquisition of investments*4 | (15.2) | (15.2) | 0.1 | (97) | ||||||||||||||||
| Proceeds from sales and redemption of investments | 26.7 | 5.6 | (21.1) | 36 | ||||||||||||||||
| Acquisition of shares in associates | — | (0.6) | (0.6) | (4) | ||||||||||||||||
| Proceeds from sales of shares in associates | — | 0.9 | 0.9 | 6 | ||||||||||||||||
| Proceeds from sales of business, net of cash and cash equivalents divested | 9.6 | 32.8 | 23.2 | 209 | ||||||||||||||||
Adjusted Free Cash Flow*1 | 568.3 | 625.9 | 57.6 | 10.1 | % | 3,992 | ||||||||||||||
*1 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations for the definitions of Free Cash Flow and Adjusted Free Cash Flow.
*2 Adjustment for cash temporarily held by Takeda on behalf of third parties refers to changes in cash balances that are temporarily held by Takeda on behalf of third parties related to vaccine operations and the trade receivables sales program, which are not available to Takeda’s immediate or general business use.
*3 Proceeds from sales of intangible assets are included in cash flow from operating activities, except certain immaterial transactions.
*4 Acquisition of JPY 80.1 billion debt investments classified as Level 1 in the fair value hierarchy is excluded for the nine-month period ended December 31, 2024.
A-12
FY2025 Q3 YTD Adjusted Net Debt to Adjusted EBITDA | |||||||||||||||||||||||
| ADJUSTED NET DEBT/ADJUSTED EBITDA RATIO | NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||||||||||||||||||||
| (Billion JPY) | FY2025 Q3 YTD | (Billion JPY) | FY2024 Q3 YTD | FY2025 Q3 YTD | JPY Change | % Change | |||||||||||||||||
| Book value of bonds and loans on consolidated statement of financial position | (4,853.3) | Net cash from operating activities (Operating Cash Flow) | 835.0 | 966.9 | 131.9 | 15.8 | % | ||||||||||||||||
| Acquisition of PP&E | (152.0) | (129.6) | |||||||||||||||||||||
| Cash & cash equivalents | 654.9 | Proceeds from sales of PP&E | 0.0 | 6.4 | |||||||||||||||||||
Net Debt*1 | (4,198.4) | Acquisition of intangible assets | (103.1) | (218.0) | |||||||||||||||||||
Application of equity credit*2 | 250.0 | Acquisition of option to license | (31.8) | (2.6) | |||||||||||||||||||
FX adjustment*3 | 217.4 | Acquisition of investments | (95.4) | (15.2) | |||||||||||||||||||
Cash temporarily held by Takeda on behalf of third parties*4 | (126.3) | Proceeds from sales and redemption of investments | 26.7 | 5.6 | |||||||||||||||||||
Level 1 debt investments*4 | 83.8 | Acquisition of shares in associates | — | (0.6) | |||||||||||||||||||
Adjusted Net Debt*1 | (3,773.6) | Proceeds from sales of shares in associates | — | 0.9 | |||||||||||||||||||
| Proceeds from sales of business, net of cash and cash equivalents divested | 9.6 | 32.8 | |||||||||||||||||||||
Adjusted EBITDA (LTM)*5 | 1,404.5 | Payments for the settlement of forward exchange contracts designated as net investment hedges | (13.9) | (1.5) | |||||||||||||||||||
| Adjusted Net Debt/Adjusted EBITDA ratio | 2.7x | Net increase (decrease) in short-term loans and commercial papers | (317.0) | (341.8) | |||||||||||||||||||
| Proceeds from long-term loans | 90.0 | — | |||||||||||||||||||||
| Book value of bonds and loans on consolidated statement of financial position | (4,853.3) | Repayment of long-term loans | (50.2) | (10.1) | |||||||||||||||||||
| Proceeds from issuance of bonds | 934.5 | 526.1 | |||||||||||||||||||||
Application of equity credit *2 | 250.0 | Repayment of bonds | (733.8) | (115.3) | |||||||||||||||||||
FX adjustment*3 | 217.4 | Proceeds from the settlement of cross currency interest rate swaps related to bonds and loans | 46.9 | — | |||||||||||||||||||
| Adjusted Gross Debt | (4,385.9) | ||||||||||||||||||||||
| Acquisition of treasury shares | (1.9) | (51.6) | |||||||||||||||||||||
| Interest paid | (78.1) | (82.1) | |||||||||||||||||||||
| Dividends paid | (292.8) | (303.1) | |||||||||||||||||||||
| Others | (34.6) | (30.6) | |||||||||||||||||||||
| Net increase (decrease) in cash and cash equivalents | 38.0 | 236.5 | 198.4 | 522.1 | % | ||||||||||||||||||
*1 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations for the definitions of Net Debt and Adjusted Net Debt.
*2 Application of equity credit includes JPY 250.0 billion reduction in debt due to a 50% equity credit applied to JPY 500.0 billion principal amount of our hybrid (subordinated) bonds and loans by S&P Global Rating Japan, given that those instruments qualify for certain equity credit for leverage purposes.
*3 FX adjustment refers to change from month-end rate to average rate used for non-JPY debt calculation outstanding at the beginning of the period to match with adjusted EBITDA (which is calculated based on average rates). New non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period are translated to JPY at relevant spot rates as of the relevant date.
*4 Adjustments related to cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, which is not available to Takeda’s immediate or general business use, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.
*5 LTM represents Last Twelve Months (January 2025 - December 2025). Calculated by subtracting FY2024 Q3 YTD from FY2024 Full Year and adding FY2025 Q3 YTD.
A-13
FY2024 Adjusted Net Debt to Adjusted EBITDA | |||||||||||||||||||||||
| ADJUSTED NET DEBT/ADJUSTED EBITDA RATIO | NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||||||||||||||||||||
| (Billion JPY) | FY2024 | (Billion JPY) | FY2023 | FY2024 | JPY Change | % Change | |||||||||||||||||
| Book value of bonds and loans on consolidated statement of financial position | (4,515.3) | Net cash from operating activities (Operating Cash Flow) | 716.3 | 1,057.2 | 340.8 | 47.6 | % | ||||||||||||||||
| Acquisition of PP&E | (175.4) | (200.8) | |||||||||||||||||||||
| Cash & cash equivalents | 385.1 | Proceeds from sales of PP&E | 8.6 | 0.1 | |||||||||||||||||||
Net Debt*1 | (4,130.2) | Acquisition of intangible assets | (305.3) | (147.0) | |||||||||||||||||||
Application of equity credit*2 | 250.0 | Acquisition of option to license | — | (31.8) | |||||||||||||||||||
FX adjustment*3 | (68.9) | Acquisition of investments | (6.8) | (97.5) | |||||||||||||||||||
Cash temporarily held by Takeda on behalf of third parties*4 | (105.8) | Proceeds from sales and redemption of investments | 8.0 | 29.4 | |||||||||||||||||||
Level 1 debt investments*4 | 79.3 | Acquisition of shares in associates | — | (1.0) | |||||||||||||||||||
Adjusted Net Debt*1 | (3,975.5) | Proceeds from sales of shares in associates | — | 57.7 | |||||||||||||||||||
| Proceeds from sales of business, net of cash and cash equivalents divested | 20.0 | 20.6 | |||||||||||||||||||||
| Adjusted EBITDA | 1,441.0 | Payments for the settlement of forward exchange contracts designated as net investment hedges | (33.3) | (13.8) | |||||||||||||||||||
| Adjusted Net Debt/Adjusted EBITDA ratio | 2.8x | Net increase (decrease) in short-term loans and commercial papers | 277.0 | 27.5 | |||||||||||||||||||
| Proceeds from long-term loans | 100.0 | 90.0 | |||||||||||||||||||||
| Book value of bonds and loans on consolidated statement of financial position | (4,515.3) | Repayment of long-term loans | (100.4) | (587.2) | |||||||||||||||||||
| Proceeds from issuance of bonds | — | 934.5 | |||||||||||||||||||||
Application of equity credit*2 | 250.0 | Repayment of bonds | (220.5) | (733.8) | |||||||||||||||||||
FX adjustment*3 | (68.9) | Proceeds from the settlement of cross currency interest rate swaps related to bonds and loans | 60.1 | 46.9 | |||||||||||||||||||
| Adjusted Gross Debt | (4,334.2) | ||||||||||||||||||||||
| Acquisition of treasury shares | (2.3) | (51.9) | |||||||||||||||||||||
| Interest paid | (100.4) | (113.0) | |||||||||||||||||||||
| Dividends paid | (287.2) | (302.5) | |||||||||||||||||||||
| Others | (60.3) | (44.6) | |||||||||||||||||||||
| Net increase (decrease) in cash and cash equivalents | (101.9) | (61.3) | 40.6 | 39.9 | % | ||||||||||||||||||
*1 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations for the definitions of Net Debt and Adjusted Net Debt.
*2 Application of equity credit includes JPY 250.0 billion reduction in debt due to a 50% equity credit applied to JPY 500.0 billion principal amount of our hybrid (subordinated) bonds and loans by S&P Global Rating Japan, given that those instruments qualify for certain equity credit for leverage purposes.
*3 FX adjustment refers to change from month-end rate to average rate used for non-JPY debt calculation outstanding at the beginning of the period to match with adjusted EBITDA (which is calculated based on average rates). New non-JPY debt incurred and existing non-JPY debt redeemed during the reporting period are translated to JPY at relevant spot rates as of the relevant date.
*4 Adjustments related to cash temporarily held by Takeda on behalf of third parties related to vaccine operations and to the trade receivables sales program, which is not available to Takeda’s immediate or general business use, and debt investments classified as Level 1 in the fair value hierarchy being recorded as Other Financial Assets.
A-14
FY2025 Q3 YTD Net Profit to Adjusted EBITDA Bridge | ||||||||||||||
| (Billion JPY) | FY2024 Q3 YTD | FY2025 Q3 YTD | JPY Change | % Change | ||||||||||
| Net profit | 211.2 | 216.3 | 5.0 | 2.4 | % | |||||||||
| Income tax expenses (benefit) | 71.1 | 96.4 | ||||||||||||
| Depreciation and amortization | 571.6 | 557.3 | ||||||||||||
| Interest expense, net | 87.8 | 97.3 | ||||||||||||
| EBITDA | 941.8 | 967.2 | 25.4 | 2.7 | % | |||||||||
| Impairment losses | 38.2 | 94.8 | ||||||||||||
| Other operating expenses (income), net, excluding depreciation and amortization, and impairment losses | 135.2 | 57.1 | ||||||||||||
| Finance expenses (income), net, excluding interest expense, net | 44.2 | 10.6 | ||||||||||||
| Share of loss (profit) of investments accounted for using the equity method | 3.2 | 1.8 | ||||||||||||
Other costs* | 51.8 | 51.1 | ||||||||||||
| Adjusted EBITDA | 1,214.4 | 1,182.7 | (31.8) | (2.6) | % | |||||||||
* Includes adjustments for non-cash items such as non-cash equity-based compensation expense, and other items that management believes are unrelated to our core operations, including purchase accounting effects and transaction related costs.
A-15
FY2025 Q3 YTD Net Profit to Adjusted EBITDA LTM Bridge | ||||||||||||||||||||
| (Billion JPY) | FY2024 Full Year (Apr - Mar) | FY2024 Q3 YTD (Apr - Dec) | FY2025 Q3 YTD (Apr - Dec) | FY2025 Q3 LTM*1 (Jan - Dec) | ||||||||||||||||
| Net profit | 108.1 | 211.2 | 216.3 | 113.2 | ||||||||||||||||
| Income tax expenses (benefit) | 66.9 | 71.1 | 96.4 | 92.2 | ||||||||||||||||
| Depreciation and amortization | 761.4 | 571.6 | 557.3 | 747.0 | ||||||||||||||||
| Interest expense, net | 117.7 | 87.8 | 97.3 | 127.2 | ||||||||||||||||
| EBITDA | 1,054.2 | 941.8 | 967.2 | 1,079.6 | ||||||||||||||||
| Impairment losses | 106.5 | 38.2 | 94.8 | 163.1 | ||||||||||||||||
| Other operating expenses (income), net, excluding depreciation and amortization, and impairment losses | 163.2 | 135.2 | 57.1 | 85.1 | ||||||||||||||||
| Finance expenses (income), net, excluding interest expense, net | 45.8 | 44.2 | 10.6 | 12.3 | ||||||||||||||||
| Share of loss (profit) of investments accounted for using the equity method | 4.0 | 3.2 | 1.8 | 2.6 | ||||||||||||||||
Other costs*2 | 67.4 | 51.8 | 51.1 | 66.7 | ||||||||||||||||
| Adjusted EBITDA | 1,441.2 | 1,214.4 | 1,182.7 | 1,409.4 | ||||||||||||||||
EBITDA from divested products*3 | (0.2) | (4.9) | ||||||||||||||||||
| Adjusted EBITDA (LTM) | 1,441.0 | 1,404.5 | ||||||||||||||||||
*1 LTM represents Last Twelve Months (January 2025 - December 2025). Calculated by subtracting FY2024 Q3 YTD from FY2024 Full Year and adding FY2025 Q3 YTD.
*2 Includes adjustments for non-cash items such as non-cash equity-based compensation expense, and other items that management believes are unrelated to our core operations, including purchase accounting effects and transaction related costs.
*3 Represents adjustments for EBITDA from divested products which are removed as part of LTM Adjusted EBITDA.
A-16
FY2025 Q3 YTD CAPEX, Depreciation and Amortization and Impairment Losses | ||
| (Billion JPY) | FY2024 Q3 YTD | FY2025 Q3 YTD | JPY Change | % Change | Revised Forecast (January 29, 2026) | |||||||||||||||||||||
Capital expenditures*1 | 255.1 | 347.6 | 92.5 | 36.3 | % | 400.0 - 450.0 | ||||||||||||||||||||
| Tangible assets | 152.0 | 129.6 | (22.4) | (14.7) | % | |||||||||||||||||||||
| Intangible assets | 103.1 | 218.0 | 114.9 | 111.4 | % | |||||||||||||||||||||
| Depreciation and amortization | 571.6 | 557.3 | (14.4) | (2.5) | % | 727.0 | ||||||||||||||||||||
Depreciation of tangible assets*2 (A) | 130.7 | 129.7 | (1.0) | (0.8) | % | |||||||||||||||||||||
| Amortization of intangible assets (B) | 441.0 | 427.6 | (13.3) | (3.0) | % | |||||||||||||||||||||
Of which Amortization on intangible assets associated with products (C) | 411.7 | 396.9 | (14.7) | (3.6) | % | 507.0 | ||||||||||||||||||||
| Of which Amortization excluding intangible assets associated with products (D) | 29.3 | 30.7 | 1.4 | 4.7 | % | |||||||||||||||||||||
| Depreciation and amortization (excluding intangible assets associated with products) (A)+(D) | 160.0 | 160.3 | 0.4 | 0.2 | % | 220.0 | ||||||||||||||||||||
| Impairment losses | 38.2 | 94.8 | 56.6 | 148.0 | % | |||||||||||||||||||||
Impairment losses on intangible assets associated with products*3 | 28.5 | 81.8 | 53.3 | 186.9 | % | 110.0 | ||||||||||||||||||||
| Amortization and impairment losses on intangible assets associated with products | 440.2 | 478.7 | 38.5 | 8.8 | % | 617.0 | ||||||||||||||||||||
| *1 Cash flow base | ||||||||||||||||||||||||||
*2 Includes depreciation of investment properties | ||||||||||||||||||||||||||
| *3 Includes in-process R&D | ||||||||||||||||||||||||||
A-17
FY2025 Full Year Detailed Forecast | ||
| (BN JPY) | Previous Forecast (October 30, 2025) | Revised Forecast (January 29, 2026) | JPY Change | % Change | Variances | ||||||||||||||||||||||||
| REPORTED | Revenue | 4,500.0 | 4,530.0 | 30.0 | 0.7% | FX benefits more than offset downward revisions to revenue outlooks for VYVANSE and other products including plasma derived therapies, TAKHZYRO, and others | |||||||||||||||||||||||
| Cost of sales | (1,590.0) | (1,595.0) | (5.0) | (0.3)% | FX headwinds partially offset by changes in product mix | ||||||||||||||||||||||||
| Gross Profit | 2,910.0 | 2,935.0 | 25.0 | 0.9% | Increase in revenue forecast, as well as favorable product mix | ||||||||||||||||||||||||
| SG&A expenses | (1,095.0) | (1,098.0) | (3.0) | (0.3)% | FX headwinds largely offset by incremental cost savings, including those from the enterprise-wide efficiency program | ||||||||||||||||||||||||
| R&D expenses | (685.0) | (687.0) | (2.0) | (0.3)% | FX headwinds largely offset by incremental cost savings, including pipeline prioritization and the enterprise-wide efficiency program | ||||||||||||||||||||||||
| Amortization of intangible assets associated with products | (497.0) | (507.0) | (10.0) | (2.0)% | Mainly due to FX | ||||||||||||||||||||||||
Impairment losses on intangible assets associated with products*1 | (110.0) | (110.0) | — | — | |||||||||||||||||||||||||
| Other operating income | 27.0 | 27.0 | — | — | |||||||||||||||||||||||||
| Other operating expenses | (150.0) | (150.0) | — | — | |||||||||||||||||||||||||
| Operating profit | 400.0 | 410.0 | 10.0 | 2.5% | |||||||||||||||||||||||||
| Finance income (expenses), net | (156.0) | (163.0) | (7.0) | (4.5)% | Mainly due to FX | ||||||||||||||||||||||||
| Profit before tax | 243.0 | 245.0 | 2.0 | 0.8% | |||||||||||||||||||||||||
| Net profit attributable to owners of the Company | 153.0 | 154.0 | 1.0 | 0.7% | |||||||||||||||||||||||||
| Basic EPS (yen) | 97 | 98 | 1 | 0.7% | |||||||||||||||||||||||||
Core Revenue*2 | 4,500.0 | 4,530.0 | 30.0 | 0.7% | FX benefits more than offset downward revisions to revenue outlooks for VYVANSE and other products including plasma derived therapies, TAKHZYRO, and others | ||||||||||||||||||||||||
Core Operating Profit*2 | 1,130.0 | 1,150.0 | 20.0 | 1.8% | Revised revenue outlooks for products largely offset by OPEX savings, plus FX benefits | ||||||||||||||||||||||||
Core EPS (yen)*2 | 479 | 486 | 7 | 1.5% | |||||||||||||||||||||||||
Adjusted Free Cash Flow*2 | 600.0 to 700.0 | 650.0 to 750.0 | Reflects the upward revision to Core OP and improvements in working capital | ||||||||||||||||||||||||||
| CAPEX (cash flow base) | (400.0) to (450.0) | (400.0) to (450.0) | |||||||||||||||||||||||||||
| Depreciation and amortization (excl. intangible assets associated with products) | (220.0) | (220.0) | — | — | |||||||||||||||||||||||||
Cash tax rate on Adjusted EBITDA (excl. divestitures)*2 | Mid teen% | Low-teen% | Reflects an expected reduction in cash taxes driven by the acceleration of U.S. R&D deductions under recent tax reform. | ||||||||||||||||||||||||||
| USD/JPY | 147 | 150 | 3 | 2.3% | |||||||||||||||||||||||||
| EUR/JPY | 170 | 174 | 3 | 2.0% | |||||||||||||||||||||||||
*1 Includes in-process R&D.
*2 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of Non-IFRS Measures and FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast.
*2 Please refer to Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations, for the definition of Non-IFRS Measures and FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast.
A-18
FY2025 Full Year Reconciliation from Reported Operating Profit to Core Operating Profit Forecast | ||
| (Billion JPY) | Reported | Reported to Core adjustments | Core | ||||||||||||||
| Amortization of intangible assets | Impairment of intangible assets | Other operating income (expenses) | |||||||||||||||
| Revenue | 4,530.0 | 4,530.0 | |||||||||||||||
| Cost of sales | (1,595.0) | (3,380.0) | |||||||||||||||
| Gross Profit | 2,935.0 | ||||||||||||||||
| SG&A expenses | (1,098.0) | ||||||||||||||||
| R&D expenses | (687.0) | ||||||||||||||||
| Amortization of intangible assets associated with products | (507.0) | 507.0 | — | ||||||||||||||
Impairment losses on intangible assets associated with products*1 | (110.0) | 110.0 | — | ||||||||||||||
| Other operating income | 27.0 | (27.0) | — | ||||||||||||||
| Other operating expenses | (150.0) | 150.0 | — | ||||||||||||||
| Operating profit | 410.0 | 507.0 | 110.0 | 123.0 | 1,150.0 | ||||||||||||
*1 Includes in-process R&D
A-19
FY2025 Full Year FX Rates Assumptions and Currency Sensitivity vs. Forecast | ||
| Average Exchange Rates vs. JPY | Impact of depreciation of yen from January 2026 to March 2026 (100 million JPY) | ||||||||||||||||||||||||||||
| FY2024 Q3 Actual (Apr-Dec) | FY2025 Q3 Actual (Apr-Dec) | FY2025 Full Year Assumption (Apr-Mar) | FY2025 Q4 Assumption (Jan-Mar) | Revenue (IFRS) | Operating Profit (IFRS) | Net Profit (IFRS) | Core Operating Profit (non-IFRS) | ||||||||||||||||||||||
| USD | 152 | 148 | 150 | 157 | 1% depreciation | 40.1 | (0.2) | (1.3) | 5.8 | ||||||||||||||||||||
| 1 yen depreciation | 25.6 | (0.1) | (0.8) | 3.7 | |||||||||||||||||||||||||
| EUR | 165 | 170 | 174 | 184 | 1% depreciation | 12.6 | (5.4) | (3.7) | (3.5) | ||||||||||||||||||||
| 1 yen depreciation | 6.9 | (2.9) | (2.0) | (1.9) | |||||||||||||||||||||||||
| RUB | 1.6 | 1.8 | 1.9 | 1.9 | 1% depreciation | 0.6 | 0.2 | 0.1 | 0.3 | ||||||||||||||||||||
| CNY | 21.1 | 20.7 | 21.1 | 22.4 | 3.7 | 2.2 | 1.4 | 2.2 | |||||||||||||||||||||
| BRL | 27.9 | 27.0 | 27.4 | 28.6 | 2.0 | 1.3 | 0.8 | 1.4 | |||||||||||||||||||||
A-20
Important Notice
For the purposes of this notice, “report” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this report. This report (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this report. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This report is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this report, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This report and any materials distributed in connection with this report may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this report or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this report may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
A-21
Financial Information and Non-IFRS Measures
Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).
This report and materials distributed in connection with this report include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this presentation. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures.
The usefulness of Core Financial Measures to investors has significant limitations including, but not limited to, (i) they are not necessarily identical to similarly titled measures used by other companies, including those in the pharmaceutical industry, (ii) they exclude financial information and events, such as the effects of non-cash expenses such as dispositions or amortization of intangible assets, that some may consider important in evaluating Takeda’s performance, value or prospects for the future, (iii) they exclude items or types of items that may continue to occur from period to period in the future (however, it is Takeda’s policy not to adjust out normal, recurring cash operating expenses necessary to operate our business) and (iv) they may not include all items which investors may consider important to an understanding of our results of operations, or exclude all items which investors may not consider to be so.
Medical Information
This report contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
A-22